1. Petty RE, Laxer RM, Lindsley CB, et al. Textbook of pediatric rheumatology. 8th ed. Philadelphia: Elsevier, Inc 2020.

2. Zaripova LN, Midgley A, Christmas SE, et al. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol. 2021; 19: 135. doi: 10.1186/s12969-021-00629-8

3. Баранов АА, Алексеева ЕИ, editors. Ревматические болезни у детей. Москва: ПедиатрЪ 2016.

4. Alexeeva EI. Juvenile idiopathic arthritis: clinical picture, diagnosis, treatment. Curr Pediatr. 2015; 14: 78 - 94. doi: 10.15690/vsp.v14i1.1266

5. Mistry RR, Patro P, Agarwal V, et al. Enthesitis-related arthritis: current perspectives. Open Access Rheumatol Res Rev. 2019; Volume 11: 19 - 31. doi: 10.2147/OARRR.S163677

6. Chen B, Li J, He C, et al. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis. Mol Med Rep. 2017; 15: 1943 - 51. doi: 10.3892/mmr.2017.6248

7. Paramarta JE, Van Der Leij C, Gofita I, et al. Peripheral joint inflammation in early onset spondyloarthritis is not specifically related to enthesitis. Ann Rheum Dis. 2014; 73: 735 - 40. doi: 10.1136/annrheumdis-2012-203155

8. Scola MP, Thompson SD, Brunner HI, et al. Interferon-gamma: interleukin 4 ratios and associated type 1 cytokine expression in juvenile rheumatoid arthritis synovial tissue. J Rheumatol. 2002; 29: 369 - 78.

9. Baerlecken NT, Nothdorft S, Stummvoll GH, et al. Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis. 2014; 73: 1211 - 4. doi: 10.1136/annrheumdis-2012-202208

10. Shukla A, Gaur P, Aggarwal A. Effect of probiotics on clinical and immune parameters in enthesitis-related arthritis category of juvenile idiopathic arthritis. Clin Exp Immunol. 2016; 185: 301 - 8. doi: 10.1111/cei.12818

11. Palman J, Shoop-Worrall S, Hyrich K, et al. Update on the epidemiology, risk factors and disease outcomes of Juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2018; 32: 206 - 22. doi: 10.1016/j.berh.2018.10.004

12. Cattalini M, Soliani M, Caparello MC, et al. Sex Differences in Pediatric Rheumatology. Clin Rev Allergy Immunol. 2019; 56: 293 - 307. doi: 10.1007/s12016-017-8642-3

13. Thierry S, Fautrel B, Lemelle I, et al. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014; 81: 112 - 7. doi: 10.1016/j.jbspin.2013.09.003

14. Burgos-Vargas R, Tse SML. Juvenile-Onset Spondyloarthritis. Handbook of Systemic Autoimmune Diseases. Elsevier 2016: 31 - 52.

15. Clarke SLN, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J. 2016; 14: 27. doi: 10.1186/s12969-016-0088-2

16. Vitale AT, Graham E, de Boer JH. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm. 2013; 21: 478 - 85. doi: 10.3109/09273948.2013.815785

17. Katargina LA, Brzheskiy VV, Guseva MR, et al. The federal clinical guidelines on "The diagnostics and treatment of uveitis associated with juvenile idiopathic arthritis." Russ Pediatr Ophthalmol. 2016; 11: 102 - 11. doi: 10.18821/1993-1859-2016-11-2-102-111

18. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004; 31: 390 - 2.

19. B, Hoffmann-Vold A, Reiff A, et al. Long-term outcome and prognostic factors in enthesitis-related arthritis: A case-control study. Arthritis Rheum. 2006; 54: 3573 - 82. doi: 10.1002/art.22181

20. Weiss PF, Beukelman T, Schanberg LE, et al. Enthesitis-related Arthritis Is Associated with Higher Pain Intensity and Poorer Health Status in Comparison with Other Categories of Juvenile Idiopathic Arthritis: The Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol. 2012; 39: 2341 - 51. doi: 10.3899/jrheum.120642

21. Oen K, Duffy CM, Tse SML, et al. Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care Res. 2010; 62: 527 - 36. doi: 10.1002/acr.20044

22. Rostom S, Amine B, Bensabbah R, et al. Hip involvement in juvenile idiopathic arthritis. Clin Rheumatol. 2008; 27: 791 - 4. doi: 10.1007/s10067-008-0853-9

23. Sherry DD, Sapp LR. Enthesalgia in childhood: site-specific tenderness in healthy subjects and in patients with seronegative enthesopathic arthropathy. J Rheumatol. 2003; 30: 1335 - 40.

24. Weiss P. Diagnosis and treatment of enthesitis-related arthritis. Adolesc Health Med Ther. 2012; 67. doi: 10.2147/AHMT.S25872

25. Minden K, Niewerth M, Listing J, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002; 46: 2392 - 401. doi: 10.1002/art.10444

26. Chen H-A, Chen C-H, Liao H-T, et al. Clinical, Functional, and Radiographic Differences Among Juvenile-onset, Adult-onset, and Late-onset Ankylosing Spondylitis. J Rheumatol. 2012; 39: 1013 - 8. doi: 10.3899/jrheum.111031

27. Weiss PF, Xiao R, Biko DM, et al. Assessment of Sacroiliitis at Diagnosis of Juvenile Spondyloarthritis by Radiography, Magnetic Resonance Imaging, and Clinical Examination. Arthritis Care Res. 2016; 68: 187 - 94. doi: 10.1002/acr.22665

28. Stoll ML, Bhore R, Dempsey-Robertson M, et al. Spondyloarthritis in a Pediatric Population: Risk Factors for Sacroiliitis. J Rheumatol. 2010; 37: 2402 - 8. doi: 10.3899/jrheum.100014

29. Maghraoui AE, Bensabbah R, Bahiri R, et al. Cervical spine involvement in ankylosing spondylitis. Clin Rheumatol. 2003; 22: 94 - 8. doi: 10.1007/s10067-002-0681-2

30. Haasnoot AJW, van Tent-Hoeve M, Wulffraat NM, et al. Erythrocyte sedimentation rate as baseline predictor for the development of uveitis in children with juvenile idiopathic arthritis. Am J Ophthalmol. 2015; 159: 372 - 377.e1. doi: 10.1016/j.ajo.2014.11.007

31. Heiligenhaus A, Minden K, D, et al. Uveitis in juvenile idiopathic arthritis. Dtsch Arzteblatt Int. 2015; 112: 92 - 100, i. doi: 10.3238/arztebl.2015.0092

32. Баранов АА, Алексеева ЕИ, Бзарова ТМ, et al. Протокол ведения пациентов с ювенильным артритом. Вопросы Современной Педиатрии. 2013; 12: 37 - 56.

33. Textbook of Pediatric Rheumatology. Elsevier 2016.

34. Koca B, Sahin S, Adrovic A, et al. Cardiac involvement in juvenile idiopathic arthritis. Rheumatol Int. 2017; 37: 137 - 42. doi: 10.1007/s00296-016-3534-z

35. Huppertz H-I, Voigt I, J, et al. Cardiac Manifestations in Patients with HLA B27-Associated Juvenile Arthritis. Pediatr Cardiol. 2000; 21: 141 - 7. doi: 10.1007/s002469910023

36. Alam MM, Ray B, Sarkar S, et al. Spirometric evaluation in juvenile idiopathic arthritis: data from eastern India. Indian J Pediatr. 2014; 81: 1010 - 4. doi: 10.1007/s12098-013-1335-x

37. Kim KH, Kim DS. Juvenile idiopathic arthritis: Diagnosis and differential diagnosis. Korean J Pediatr. 2010; 53: 931 - 5. doi: 10.3345/kjp.2010.53.11.931

38. Jeamsripong S, Charuvanij S. Features distinguishing juvenile idiopathic arthritis among children with musculoskeletal complaints. World J Pediatr WJP. 2020; 16: 74 - 81. doi: 10.1007/s12519-018-0212-0

39. Hu-Torres S, Foster CS. Disease of the year: juvenile idiopathic arthritis--differential diagnosis. Ocul Immunol Inflamm. 2014; 22: 42 - 55. doi: 10.3109/09273948.2013.835430

40. Al-Mayouf SM. Noninflammatory disorders mimic juvenile idiopathic arthritis. Int J Pediatr Adolesc Med. 2018; 5: 1 - 4. doi: 10.1016/j.ijpam.2018.01.004

41. Brix N, S, Glerup M, et al. Identifying acute lymphoblastic leukemia mimicking juvenile idiopathic arthritis in children. PloS One. 2020; 15: e0237530. doi: 10.1371/journal.pone.0237530

42. Okamoto N, Yokota S, Takei S, et al. Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018. Mod Rheumatol. 2019; 29: 41 - 59. doi: 10.1080/14397595.2018.1514724

43. Nordal EB, Zak M, Aalto K, et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis. 2012; 71: 1122 - 7. doi: 10.1136/annrheumdis-2011-200237

44. Breda, L., Nozzi, M., De Sanctis, S., & Chiarelli, F. (2010). Laboratory Tests in the Diagnosis and Follow-Up of Pediatric Rheumatic Diseases: An Update. Seminars in Arthritis and Rheumatism, 40(1), 53 - 72. doi: 10.1016/j.semarthrit.2008.12.

45. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis Rheumatol. 2022; 74: 570 - 85. doi: 10.1002/art.42036

46. Тепаев РФ. Синдром диссеминированного внутрисосудистого свертывания у детей. Диагностика и лечение. Педиатрическая Фармакология. 2010; 7: 27 - 31.

47. Rajagopal R, Thachil J, Monagle P. Disseminated intravascular coagulation in paediatrics. Arch Dis Child. 2017; 102: 187 - 93. doi: 10.1136/archdischild-2016-311053

48. De Vere-Tyndall A, Macauley D, Ansell BM. Disseminated intravascular coagulation complicating systemic juvenile chronic arthritis ("Still's disease"). Clin Rheumatol. 1983; 2: 415 - 8. doi: 10.1007/BF02041564

49. Gallistl S, Mangge H, Neuwirth G, et al. Activation of the haemostatic system in children with juvenile rheumatoid arthritis correlates with disease activity. Thromb Res. 1998; 92: 267 - 72. doi: 10.1016/s0049-3848(98)00145-5

50. Ameri A, Anderson CM, Smith JH, et al. Thromboembolic Complications in a Pediatric Patient Population: Treatment with Direct Oral Anticoagulants. Monitoring of Treatment Efficiency with D-Dimer Levels and Safety Profile By Thromboelastogram. Blood. 2021; 138: 4270 - 4270. doi: 10.1182/blood-2021-146948

51. Oren H, I, Duman M, et al. Disseminated intravascular coagulation in pediatric patients: clinical and laboratory features and prognostic factors influencing the survival. Pediatr Hematol Oncol. 2005; 22: 679 - 88. doi: 10.1080/08880010500278749

52. Scott C., Slamang W. Biologics in childhood rheumatic disorders//Current Allergy & Clinical Immunology. - 2018. - Т. 31. - N. 4. - С. 206 - 211.

53. Schapkaitz E, Sherman GG, Jacobson BF, et al. Paediatric anticoagulation guidelines. S Afr Med J. 2012; 102: 171. doi: 10.7196/SAMJ.5471

54. Manco-Johnson MJ. How I treat venous thrombosis in children. Blood. 2006; 107: 21 - 9. doi: 10.1182/blood-2004-11-4211

55. Tolbert J, Carpenter SL. Common Acquired Causes of Thrombosis in Children. Curr Probl Pediatr Adolesc Health Care. 2013; 43: 169 - 77. doi: 10.1016/j.cppeds.2013.05.005

56. M P, Salgado U A, Barriga G J, et al. Usefulness of the thromboelastogram in children: correlation with habitual coagulation tests. Rev Chil Pediatr. 2019; 90: 617 - 23. doi: 10.32641/rchped.v90i6.930

57. Геморрагические и тромботические заболевания и синдромы у детей и подростков: патогенез, клиника, диагностика, терапия и профилактика: монография/Б.И. Кузник, В.Г. Стуров, Н.Ю. Левшин [и др.]. - 2-е изд., перераб. и доп. - Новосибирск: Наука, 2018. - 524 с.

58. Verma A, Hemlata. Thromboelastography as a novel viscoelastic method for hemostasis monitoring: Its methodology, applications, and constraints. Glob J Transfus Med. 2017; 2: 8. doi: 10.4103/GJTM.GJTM_4_17

59. Yuan W-H, Liu H-C, Zeng L-K, et al. [Change of Thrombelastography in Children's DIC and Analysis of Its Sensitivity and Specificity for Diagnosis of DIC]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2017; 25: 847 - 52. doi: 10.7534/j.issn.1009-2137.2017.03.039.

60. Михельсон, В.А., В.А. Сидоров, and С.М. Степаненко. "Анестезия и интенсивная терапия в педиатрии." М.: "Дель рус (2007).

61. Голуб И.Е., Сорокина Л.В. Избранные вопросы по общей анестезиологии (методические рекомендации для клинических ординаторов, с правом переиздания). - 2005.

62. Nik A, Mirfeizi Z, Rezaieyazdi Z, et al. ABO and Rh blood groups in patients with Lupus and Rheumatoid Arthritis. Casp J Intern Med. 2021; 12. doi: 10.22088/cjim.12.4.568

63. Salem GI, Gamal NM, Talaat EA, et al. Clinical Impact of the ABO Blood Type in Patients with Rheumatic Diseases: Is there a Link to the ABO and Rhesus? Mediterr J Rheumatol. 2021; 32: 237. doi: 10.31138/mjr.32.3.237

64. Sarkar S, Alam MM, Das G, et al. Inflammatory Markers and Disease Activity in Juvenile Idiopathic Arthritis. Indian J Pediatr. 2017; 84: 349 - 56. doi: 10.1007/s12098-017-2292-6

65. Horneff G, Klein A, Ganser G, et al. Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2017; 15: 78. doi: 10.1186/s12969-017-0206-9

66. John RM, Kenney-Riley K. Care of the Child with a Possible Rheumatological Disorder. In: John RM, ed. Pediatric Diagnostic Labs for Primary Care: An Evidence-based Approach. Cham: Springer International Publishing 2022: 461 - 86.

67. Cortis E, Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr. 2006; 95: 38 - 41. doi: 10.1111/j.1651-2227.2006.tb02414.x

68. Gilliam BE, Chauhan AK, Low JM, et al. Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. Clin Exp Rheumatol. 2008; 26: 492 - 7.

69. Marzan KAB, Shaham B. Early Juvenile Idiopathic Arthritis. Rheum Dis Clin N Am. 2012; 38: 355 - 72. doi: 10.1016/j.rdc.2012.04.006

70. Mahmud SA, Binstadt BA. Autoantibodies in the Pathogenesis, Diagnosis, and Prognosis of Juvenile Idiopathic Arthritis. Front Immunol. 2018; 9: 3168. doi: 10.3389/fimmu.2018.03168

71. Syed RH, Gilliam BE, Moore TL. Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology. Curr Rheumatol Rep. 2008; 10: 156 - 63. doi: 10.1007/s11926-008-0027-4

72. Barash J, Goldzweig O. Possible role of streptococcal infection in flares of juvenile idiopathic arthritis. Arthritis Rheum. 2007; 57: 877 - 80. doi: 10.1002/art.22787

73. Nishibukuro M, Tsutsumi N, Chiyotanda M, et al. Poststreptococcal reactive arthritis in Japan. J Infect Chemother Off J Jpn Soc Chemother. 2018; 24: 531 - 7. doi: 10.1016/j.jiac.2018.02.012

74. Srivastava R, Phatak S, Yadav A, et al. HLA B27 typing in 511 children with juvenile idiopathic arthritis from India. Rheumatol Int. 2016; 36: 1407 - 11. doi: 10.1007/s00296-016-3529-9

75. Z, Turowska-Heydel D, Sobczyk M, et al. Prevalence of HLA-B27 antigen in patients with juvenile idiopathic arthritis. Reumatologia. 2015; 53: 125 - 30. doi: 10.5114/reum.2015.53133

76. Ahn JG. Role of Biomarkers in Juvenile Idiopathic Arthritis. J Rheum Dis. 2020; 27: 233 - 40. doi: 10.4078/jrd.2020.27.4.233

77. Ben-Chetrit E, Gattorno M, Gul A, et al. Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Ann Rheum Dis. 2018; 77: 1558 - 65. doi: 10.1136/annrheumdis-2017-212515

78. Adrovic A, Sahin S, Barut K, et al. Familial Mediterranean fever and periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome: shared features and main differences. Rheumatol Int. 2019; 39: 29 - 36. doi: 10.1007/s00296-018-4105-2

79. Bourguiba R, Savey L, Aouba A, et al. Le syndrome de aux mutations du du au TNF de type 1: un diagnostic de la familiale ne pas chez les patients d'origine . Rev Interne. 2021; 42: 459 - 64. doi: 10.1016/j.revmed.2020.08.007

80. Sag E, Bilginer Y, Ozen S. Autoinflammatory Diseases with Periodic Fevers. Curr Rheumatol Rep. 2017; 19: 41. doi: 10.1007/s11926-017-0670-8

81. Soon GS, Laxer RM. Approach to recurrent fever in childhood. Can Fam Physician Med Fam Can. 2017; 63: 756 - 62.

82. Hashkes PJ, Laxer RM, Simon A, editors. Textbook of Autoinflammation. Cham: Springer International Publishing 2019.

83. Щербина АЮ. Первичные иммунодефициты - реалии XXI века. Вопросы Гематологиионкологии И Иммунопатологии В Педиатрии. 2016; 15: 8-9-9. https://www.hemoncim.com/jour/article/view/142 (accessed 14 April 2020)

84. Zahran AM, Abdallah AM, Saad K, et al. Peripheral Blood B and T Cell Profiles in Children with Active Juvenile Idiopathic Arthritis. Arch Immunol Ther Exp (Warsz). 2019; 67: 427 - 32. doi: 10.1007/s00005-019-00560-7

85. Quesada-Masachs E, De La Sierra D, Garcia Prat M, et al. AB0165 In Depth Immunophenotypic Analysis In Juvenile Idiopathic Arthritis (JIA): A Crossectional Study. Ann Rheum Dis. 2016; 75: 952.3 - 953. doi: 10.1136/annrheumdis-2016-eular.4823

86. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res. 2013; 65: 1551 - 63. doi: 10.1002/acr.22087

87. Barut K, S, Adrovic A, et al. Tuberculin skin test response in patients with juvenile idiopathic arthritis on anti-TNF therapy. Turk J Med Sci. 2018; 48: 1109 - 14. doi: 10.3906/sag-1710-190

88. AL, DiNardo A, Saavedra B, et al. Point of care diagnostics for tuberculosis. Pulmonology. 2018; 24: 73 - 85. doi: 10.1016/j.rppnen.2017.12.002

89. Brunelli JB, Bonfiglioli KR, Silva CA, et al. Latent tuberculosis infection screening in juvenile idiopathic arthritis patients preceding anti-TNF therapy in a tuberculosis high-risk country. Rev Bras Reumatol. 2017; 57: 392 - 6. doi: 10.1016/j.rbre.2016.11.004

90. Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015; 14: 503 - 9. doi: 10.1016/j.autrev.2015.01.011

91. Аксенова ВА, Барышников ЛА, Клевно НИ, et al. Новые возможности скрининга и диагностики различных проявлений туберкулезной инфекции у детей и подростков в России. Вопросы Современной Педиатрии. 2011; 10: 16 - 22.

92. Aksenova VA, Klevno NI, Kazakov AV, et al. Preventive Tuberculosis Services Reduces the Risk of Local Forms of Tuberculosis Development in Children on Immunosuppressive Therapy: Retrospective Cohort Study. Curr Pediatr. 2020; 19: 346 - 51. doi: 10.15690/vsp.v19i5.2210

93. J, Anton J, De Carpi J, et al. Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before inhibitor initiation in children in Spain. Eur J Pediatr. 2022; 182: 307 - 17. doi: 10.1007/s00431-022-04640-3

94. Бармина НА, Барышникова ЛА, Шурыгин АА, et al. Скрининговое обследование детей и подростков III, IV и V групп здоровья с применением нового диагностического теста. Туберкулез И Болезни Легких. 2015; 0: 40 - 1.

95. Selmi C, Gershwin ME. Diagnosis and classification of reactive arthritis. Autoimmun Rev. 2014; 13: 546 - 9. doi: 10.1016/j.autrev.2014.01.005

96. Bentaleb I, Abdelghani KB, Rostom S, et al. Reactive Arthritis: Update. Curr Clin Microbiol Rep. 2020; 1 - 9. doi: 10.1007/s40588-020-00152-6

97. Zeidler H, Hudson AP. Reactive Arthritis Update: Spotlight on New and Rare Infectious Agents Implicated as Pathogens. Curr Rheumatol Rep. 2021; 23: 53. doi: 10.1007/s11926-021-01018-6

98. Dembek ZF, Mothershead JL, Owens AN, et al. Psittacosis: An Underappreciated and Often Undiagnosed Disease. Pathogens. 2023; 12: 1165. doi: 10.3390/pathogens12091165

99. Singh A, Karrar S. The Role of Intracellular Organisms in the Pathogenesis of Inflammatory Arthritis. Int J Inflamm. 2014; 2014: 1 - 8. doi: 10.1155/2014/158793

100. Taccetti G, Trapani S, Ermini M, et al. Reactive arthritis triggered by Yersinia enterocolitica: a review of 18 pediatric cases. Clin Exp Rheumatol. 1994; 12: 681 - 4.

101. Williams G. F. et al. Post-Yersinia Arthritis//Western Journal of Medicine. - 1980. - Т. 132. - N. 6. - С. 535.

102. Yang W-C, Huang Y-C, Tsai M-H, et al. Salmonella Septic Arthritis Involving Multiple Joints in a Girl with Acute Lymphoblastic Leukemia at Diagnosis. Pediatr Neonatol. 2009; 50: 33 - 5. doi: 10.1016/S1875-9572(09)60027-9

103. Kanakoudi-Tsakalidou, G Pardalos, P F. Persistent or Severe Course of Reactive Arthritis Following Salmonella enteritidis Infection: A prospective study of 9 cases. Scand J Rheumatol. 1998; 27: 431 - 4. doi: 10.1080/030097498442253

104. Kurniawan A, Sitorus IP, Loho T, et al. A rare case of septic arthritis of the knee caused by Salmonella typhi with preexisting typhoid fever in a healthy, immunocompetent child - A case report. Int J Surg Case Rep. 2021; 78: 76 - 80. doi: 10.1016/j.ijscr.2020.12.003

105. Leino R, A-L, Tiilikainen A, et al. Yersinia Arthritis in Children. Scand J Rheumatol. 1980; 9: 245 - 9. doi: 10.3109/03009748009112357

106. Hannu T. Reactive arthritis after an outbreak of Yersinia pseudotuberculosis serotype O: 3 infection. Ann Rheum Dis. 2003; 62: 866 - 9. doi: 10.1136/ard.62.9.866

107. Jezequel C, Prigent JY, Loiseau-Corvez MN, et al. [Reactive arthritis caused by Yersinia in children. Report of 4 cases]. Ann Pediatr (Paris). 1991; 38: 318 - 22.

108. Naija O. et al. A new case of reactive arthritis following Yersinia pseudotuberculosis serotype IV//Journal of Pediatric Infectious Diseases. - 2010. - Т. 5. - N. 02. - С. 193 - 194.

109. Orczyk K, J, Smolewska E. When a patient suspected with juvenile idiopathic arthritis turns out to be diagnosed with an infectious disease - a review of Lyme arthritis in children. Pediatr Rheumatol Online J. 2017; 15: 35. doi: 10.1186/s12969-017-0166-0

110. Sood SK. Lyme Disease in Children. Infect Dis Clin North Am. 2015; 29: 281 - 94. doi: 10.1016/j.idc.2015.02.011

111. Steffen, Hirsch. Diagnostik der Lyme-Borreliose. Ther Umsch. 2005; 62: 737 - 44. doi: 10.1024/0040-5930.62.11.737

112. Giancane G, Swart JF, Castagnola E, et al. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Res Ther. 2020; 22: 71. doi: 10.1186/s13075-020-02167-2

113. Houen G, Trier NH. Epstein-Barr Virus and Systemic Autoimmune Diseases. Front Immunol. 2020; 11: 587380. doi: 10.3389/fimmu.2020.587380

114. Shi T, Huang L, Tian J. Prevalence of Epstein-Barr Viral DNA among children at a single hospital in Suzhou, China. J Pediatr (Rio J). 2022; 98: 142 - 6. doi: 10.1016/j.jped.2021.05.006

115. Kharitonova LA, Soboleva NG. The role of the infectious factor in juvenile rheumatoid arthritis in children. Ross Vestn Perinatol Pediatr Russ Bull Perinatol Pediatr. 2018; 63: 59 - 63. doi: 10.21508/1027-4065-2018-63-3-59-63

116. Engelmann I, Petzold DR, Kosinska A, et al. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J Med Virol. 2008; 80: 467 - 77. doi: 10.1002/jmv.21095

117. Солдатова Е.Ю. и др. Распространенность герпесвирусной инфекции у больных с различными формами и вариантами ювенильного артрита//Лечащий врач. - 2017. - N. 6. - С. 31 - 31.

118. Banko A, Cirkovic A, Jeremic I, et al. Uncovering the Role of Epstein-Barr Virus Infection Markers for Remission in Rheumatoid Arthritis. Biomedicines. 2023; 11: 2375. doi: 10.3390/biomedicines11092375

119. for the Paediatric Rheumatology International Trials Organisation (PRINTO), Giancane G, Swart JF, et al. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Res Ther. 2020; 22: 71. doi: 10.1186/s13075-020-02167-2

120. Liu Z, Zhang P, Tang S, et al. Urine real-time polymerase chain reaction detection for children virus pneumonia with acute human cytomegalovirus infection. BMC Infect Dis. 2014; 14: 245. doi: 10.1186/1471-2334-14-245

121. A. Ross S, Novak Z, Pati S, et al. Overview of the Diagnosis of Cytomegalovirus Infection. Infect Disord - Drug Targets. 2011; 11: 466 - 74. doi: 10.2174/187152611797636703

122. Slots J, Slots H. Bacterial and viral pathogens in saliva: disease relationship and infectious risk. Periodontol 2000. 2011; 55: 48 - 69. doi: 10.1111/j.1600-0757.2010.00361.x

123. Strick LB, Wald A. Diagnostics for Herpes Simplex Virus: Is PCR the New Gold Standard? Mol Diagn Ther. 2006; 10: 17 - 28. doi: 10.1007/BF03256439

124. Vince A, Dusek D. Imunosupresija i virusne infekcije u reumatskim bolestima [Immunosupression and viral infections in rheumatic diseases]. Reumatizam. 2007; 54(2): 58 - 62. Croatian. PMID: 18351141.

125. Eisenstein EM, Wolf DG. Cytomegalovirus infection in pediatric rheumatic diseases: a review. Pediatr Rheumatol. 2010; 8: 17. doi: 10.1186/1546-0096-8-17

126. Hanson V, Kornreich HK, Drexler E, et al. Some Immunologic Considerations in Focal Scleroderma and Progressive Systemic Sclerosis in Children. Pediatr Res. 1974; 8: 806 - 9. doi: 10.1203/00006450-197409000-00006

127. Looker KJ, Magaret AS, May MT, et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PloS One. 2015; 10: e0140765. doi: 10.1371/journal.pone.0140765

128. McQuillan G, Kruszon-Moran D, Flagg EW, et al. Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14 - 49: United States, 2015 - 2016. NCHS Data Brief. 2018; 1 - 8.

129. Xu F, Lee FK, Morrow RA, et al. Seroprevalence of herpes simplex virus type 1 in children in the United States. J Pediatr. 2007; 151: 374 - 7. doi: 10.1016/j.jpeds.2007.04.065

130. Levin MJ, Weinberg A, Schmid DS. Herpes Simplex Virus and Varicella-Zoster Virus. Microbiol Spectr. 2016; 4. doi: 10.1128/microbiolspec.DMIH2-0017-2015

131. McAuley JB. Congenital Toxoplasmosis. J Pediatr Infect Dis Soc. 2014; 3 Suppl 1: S30 - 35. doi: 10.1093/jpids/piu077

132. McAuley JB. Toxoplasmosis in Children. Pediatr Infect Dis J. 2008; 27: 161 - 2. doi: 10.1097/INF.0b013e3181658abb

133. Villard O, Cimon B, L'Ollivier C, et al. Serological diagnosis of Toxoplasma gondii infection. Diagn Microbiol Infect Dis. 2016; 84: 22 - 33. doi: 10.1016/j.diagmicrobio.2015.09.009

134. Dong W, Zhong Q, Gu Y-L, et al. Is Toxoplasma gondii infection a concern in individuals with rheumatic diseases? Evidence from a case-control study based on serological diagnosis. Microb Pathog. 2023; 182: 106257. doi: 10.1016/j.micpath.2023.106257

135. Salem DA, Al-Ghamdi AH, Alghamdi JM, et al. Toxoplasma and Toxocara seropositivity in juvenile idiopathic arthritis and its relation to disease activity and type of therapies. Food Waterborne Parasitol. 2023; 31: e00195. doi: 10.1016/j.fawpar.2023.e00195

136. Abdolsalehi M, Pourakbari B, Mahmoudi S, et al. Clinical and Epidemiologic Features of Visceral Leishmaniasis in Children: A 6-year Study from an Iranian Referral Hospital. Infect Disord Drug Targets. 2020; 20: 461 - 6. doi: 10.2174/1871526519666190613123217

137. Aronson NE, Joya CA. Cutaneous Leishmaniasis: Updates in Diagnosis and Management. Infect Dis Clin North Am. 2019; 33: 101 - 17. doi: 10.1016/j.idc.2018.10.004

138. Cascio A., Colomba C. Childhood Mediterranean visceral leishmaniasis//Le Infezioni in Medicina. - 2003. - Т. 11. - N. 1. - С. 5 - 10.

139. A, Mateo L, Lloveras N, et al. Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. Joint Bone Spine. 2010; 77: 271 - 3. doi: 10.1016/j.jbspin.2010.01.011

140. Kurizky PS, Marianelli FF, Cesetti MV, et al. A comprehensive systematic review of leishmaniasis in patients undergoing drug-induced immunosuppression for the treatment of dermatological, rheumatological and gastroenterological diseases. Rev Inst Med Trop Paulo. 2020; 62: e28. doi: 10.1590/s1678-9946202062028

141. Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019; 4: 466 - 76. doi: 10.1016/S2468-1253(19)30042-1

142. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67: 370 - 98. doi: 10.1016/j.jhep.2017.03.021

143. Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019; 4: 477 - 87. doi: 10.1016/S2468-1253(19)30046-9

144. Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatol Baltim Md. 2020; 72: 671 - 722. doi: 10.1002/hep.31065

145. Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67: 370 - 98. doi: 10.1016/j.jhep.2017.03.021

146. Harrison MJ, Brice N, Scott C. Clinical Features of HIV Arthropathy in Children: A Case Series and Literature Review. Front Immunol. 2021; 12: 677984. doi: 10.3389/fimmu.2021.677984

147. World Health Organization. WHO recommendations on the diagnosis of HIV infection in infants and children. World Health Organization, 2010.

148. Reust CE. Evaluation of primary immunodeficiency disease in children. Am Fam Physician. 2013; 87: 773 - 8.

149. Key recommendations. WHO Recommendations on the Diagnosis of HIV Infection in Infants and Children. World Health Organization 2010.

150. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med. 2020; 46: 10 - 67. doi: 10.1007/s00134-019-05878-6

151. Howell MD, Davis AM. Management of Sepsis and Septic Shock. JAMA. 2017; 317: 847. doi: 10.1001/jama.2017.0131

152. Trachtman R, Murray E, Wang CM, et al. Procalcitonin Differs in Children With Infection and Children With Disease Flares in Juvenile Idiopathic Arthritis. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2021; 27: 87 - 91. doi: 10.1097/RHU.0000000000001170

153. Limper M, de Kruif MD, Duits AJ, et al. The diagnostic role of Procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. J Infect. 2010; 60: 409 - 16. doi: 10.1016/j.jinf.2010.03.016

154. Chien Y-L, Huang F-L, Huang C-M, et al. Clinical approach to fever of unknown origin in children. J Microbiol Immunol Infect. 2017; 50: 893 - 8. doi: 10.1016/j.jmii.2015.08.007

155. Ahmadinejad Z, Mansori S, Ziaee V, et al. Periodic Fever: a review on clinical, management and guideline for Iranian patients - part I. Iran J Pediatr 2014; 24: 1 - 13.

156. H, I, Duman M, et al. Disseminated intravascular coagulation in pediatric patients: Clinical and Laboratory Features and Prognostic Factors Influencing the Survival. Pediatr Hematol Oncol. 2005; 22: 679 - 88. doi: 10.1080/08880010500278749

157. Robinson JL, Lee BE, Kothapalli S, et al. Use of Throat Swab or Saliva Specimens for Detection of Respiratory Viruses in Children. Clin Infect Dis. 2008; 46: e61 - 4. doi: 10.1086/529386

158. Hurd A, Beukelman T. Infectious Complications in Juvenile Idiopathic Arthritis. Curr Rheumatol Rep. 2013; 15: 327. doi: 10.1007/s11926-013-0327-1

159. Del Giudice E, Marcellino A, Hoxha S, et al. Proteinuria and hematuria as early signs of renal involvement in juvenile idiopathic arthritis. Front Pediatr. 2024; 12: 1395961. doi: 10.3389/fped.2024.1395961

160. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. Published Online First: 5 June 2014. doi: 10.1016/j.crohns.2014.04.005

161. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care - An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018; 67: 257 - 91. doi: 10.1097/MPG.0000000000002035

162. Ferrara G, Pastore S, Sancin L, et al. Fecal Calprotectin to Detect Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis. J Rheumatol. 2018; 45: 1418 - 21. doi: 10.3899/jrheum.171200

163. Boylan M. Should ultrasound be used routinely in the diagnosis of rheumatoid arthritis? Ir J Med Sci. 2020; 189: 735 - 48. doi: 10.1007/s11845-019-02096-3

164. Basra HAS, Humphries PD. Juvenile idiopathic arthritis: what is the utility of ultrasound? Br J Radiol. 2017; 90: 20160920. doi: 10.1259/bjr.20160920

165. Chauvin NA, Doria AS. Ultrasound imaging of synovial inflammation in juvenile idiopathic arthritis. Pediatr Radiol. 2017; 47: 1160 - 70. doi: 10.1007/s00247-017-3934-6

166. Malattia C, Rinaldi M, Martini A. The role of imaging in juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2018; 14: 681 - 94. doi: 10.1080/1744666X.2018.1496019

167. Balassy C, Miller SF. CT in children's bones and joints: When, how and common findings. Eur J Radiol. 2013; 82: 1126 - 34. doi: 10.1016/j.ejrad.2011.12.007

168. Allen-Rhoades W, Whittle SB, Rainusso N. Pediatric Solid Tumors in Children and Adolescents: An Overview. Pediatr Rev. 2018; 39: 444 - 53. doi: 10.1542/pir.2017-0268

169. Zucker EJ, Lee EY, Restrepo R, et al. Hip disorders in children. AJR Am J Roentgenol. 2013; 201: W776 - 796. doi: 10.2214/AJR.13.10623

170. Munir S, Patil K, Miller E, et al. Juvenile idiopathic arthritis of the axial joints: a systematic review of the diagnostic accuracy and predictive value of conventional MRI. AJR Am J Roentgenol. 2014; 202: 199 - 210. doi: 10.2214/AJR.12.10475

171. Yilmaz MH, Ozbayrak M, Kasapcopur O, et al. Pelvic MRI findings of juvenile-onset ankylosing spondylitis. Clin Rheumatol. 2010; 29: 1007 - 13. doi: 10.1007/s10067-010-1514-3

172. Vendhan K, Sen D, Fisher C, et al. Inflammatory Changes of the Lumbar Spine in Children and Adolescents With Enthesitis-Related Arthritis: Magnetic Resonance Imaging Findings. Arthritis Care Res. 2014; 66: 40 - 6. doi: 10.1002/acr.22201

173. Schiettecatte E, Jans L, Jaremko JL, et al. MR Imaging of Rheumatic Diseases Affecting the Pediatric Population. Semin Musculoskelet Radiol. 2021; 25: 082 - 93. doi: 10.1055/s-0041-1726435

174. Sheybani EF, Khanna G, White AJ, et al. Imaging of Juvenile Idiopathic Arthritis: A Multimodality Approach. RadioGraphics. 2013; 33: 1253 - 73. doi: 10.1148/rg.335125178

175. A, R, JM, et al. Clinical examination and imaging resources in children and adolescent back pain. J Child Orthop. 2023; 17: 512 - 26. doi: 10.1177/18632521231215860

176. Goirand M, Breton S, Chevallier F, et al. Clinical features of children with enthesitis-related juvenile idiopathic arthritis/juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre. Pediatr Rheumatol. 2018; 16: 21. doi: 10.1186/s12969-018-0238-9

177. Azouz EM, Duffy CM. Juvenile spondyloarthropathies: clinical manifestations and medical imaging. Skeletal Radiol. 1995; 24: 399 - 408. doi: 10.1007/BF00941234

178. Weiss PF, Colbert RA. Radiography Versus Magnetic Resonance Imaging (MRI) in Juvenile Spondyloarthritis: Is the MR Image Everything? J Rheumatol. 2014; 41: 832 - 3. doi: 10.3899/jrheum.140212

179. Stefanski A-L, Tomiak C, Pleyer U, et al. The Diagnosis and Treatment of Syndrome. Dtsch Arzteblatt Int. 2017; 114: 354 - 61. doi: 10.3238/arztebl.2017.0354

180. D'Arco F, Ugga L. Computed tomography and magnetic resonance imaging in pediatric salivary gland diseases: a guide to the differential diagnosis. Pediatr Radiol. 2020; 50: 1293 - 307. doi: 10.1007/s00247-020-04684-3

181. Takagi Y, Sasaki M, Eida S, et al. Comparison of salivary gland MRI and ultrasonography findings among patients with syndrome over a wide age range. Rheumatology. 2022; 61: 1986 - 96. doi: 10.1093/rheumatology/keab560

182. Krumrey-Langkammerer M, Haas J-P. Salivary gland ultrasound in the diagnostic workup of juvenile syndrome and mixed connective tissue disease. Pediatr Rheumatol. 2020; 18: 44. doi: 10.1186/s12969-020-00437-6

183. Dumaine C, Bekkar S, Belot A, et al. Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte. Joint Bone Spine. 2020; 87: 49 - 55. doi: 10.1016/j.jbspin.2019.07.011

184. Sierra D, Wood M, Kolli S, et al. Pediatric Gastritis, Gastropathy, and Peptic Ulcer Disease. Pediatr Rev. 2018; 39: 542 - 9. doi: 10.1542/pir.2017-0234

185. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 2017; 64: 991 - 1003. doi: 10.1097/MPG.0000000000001594

186. Бзарова Т.М., Щербаков П.Л., Алексеева Е.И., Чистякова Е.Г., and Валиева С.И. "Лечение гастроэзофагеальной рефлюксной болезни у детей с юношеским артритом" Вопросы современной педиатрии, vol. 6, no. 4, 2007, pp. 17 - 22.

187. Kotilea K, Cadranel S, Salame A, et al. Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children. Helicobacter. 2021; 26: e12825. doi: 10.1111/hel.12825

188. Бельмер С.В., Корниенко Е.А., Волынец Г.В., Гурова М.М., Звягин А.А., Камалова А.А., Луппова Н.Е., Нижевич А.А., Новикова В.П., Печкуров Д.В., Приворотский В.Ф., Сатаев В.У., Тяжева А.А., Файзуллина Р.А., Хавкин А.И. Диагностика и лечение хеликобактерной инфекции у детей. Экспериментальная и клиническая гастроэнтерология. 2021; (9): 119 - 127. https://doi.org/10.31146/1682-8658-ecg-193-9-119-127.

189. Pichler J, Ong C, Shah N, et al. Histopathological features of gastrointestinal mucosal biopsies in children with juvenile idiopathic arthritis. Pediatr Res. 2016; 79: 895 - 901. doi: 10.1038/pr.2016.27

190. Ashorn M, Verronen P, Ruuska T, et al. Upper endoscopic findings in children with active juvenile chronic arthritis. Acta Paediatr. 2003; 92: 558 - 61. doi: 10.1111/j.1651-2227.2003.tb02506.x

191. Len C, Hilario MO, Kawakami E, et al. Gastroduodenal lesions in children with juvenile rheumatoid arthritis. Hepatogastroenterology. 1999; 46: 991 - 6.

192. Weber P, Brune T, Ganser G, et al. Gastrointestinal symptoms and permeability in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2003; 21: 657 - 62.

193. Листопадова А.П. и др. Этиологическая структура хронического гастрита у детей, больных ювенильным хроническим артритом//Актуальные проблемы медицины. - 2014. - Т. 28. - N. 24 (195). - С. 33 - 36.

194. Maller J, Fox E, Park KT, et al. Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis. J Rheumatol. 2021; 48: 567 - 74. doi: 10.3899/jrheum.200230

195. Broekaert IJ, Klein A, Windschall D, et al. Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics. J Pediatr Gastroenterol Nutr. 2023; 76: 174 - 82. doi: 10.1097/MPG.0000000000003656

196. Passo MH, Fitzgerald JF, Brandt KD. Arthritis associated with inflammatory bowel disease in children: Relationship of joint disease to activity and severity of bowel lesion. Dig Dis Sci. 1986; 31: 492 - 7. doi: 10.1007/BF01320313

197. Biswas S. et al. IBD-Associated Arthritis Misdiagnosed as Juvenile Idiopathic Arthritis: A Case Report and Literature Review: 2091//Official journal of the American College of Gastroenterology| ACG. - 2018. - Т. 113. - С. S1188 - S1189.

198. Pedraz L, Galindo Zavala R, Blasco Alonso J, et al. Crohn's disease in a patient with systemic onset juvenile idiopathic arthritis. Association or associated side effect of treatment? Reumatol Engl Ed. 2022; 18: 557 - 9. doi: 10.1016/j.reumae.2021.06.004

199. De Cock D, Hyrich K. Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management. Best Pract Res Clin Rheumatol. 2018; 32: 869 - 86. doi: 10.1016/j.berh.2019.03.011

200. Lobo L, Antunes D. Chest CT in infants and children. Eur J Radiol. 2013; 82: 1108 - 17. doi: 10.1016/j.ejrad.2011.12.006

201. Quezada A, Ramos S, Garcia M, et al. Lung involvement in rheumatologic diseases in children. Allergol Immunopathol (Madr). 2012; 40: 88 - 91. doi: 10.1016/j.aller.2011.02.009

202. Nikishina I, Kolkhidova Z, Blank L, et al. AB1260 Significance of whole-body mri in children with rheumatic diseases. Ann Rheum Dis. 2022; 81: 1739.3 - 1740. doi: 10.1136/annrheumdis-2022-eular.4671

203. Eutsler EP, Khanna G. Whole-body magnetic resonance imaging in children: technique and clinical applications. Pediatr Radiol. 2016; 46: 858 - 72. doi: 10.1007/s00247-016-3586-y

204. Fonseca MB, Gomes FHR, Valera ET, et al. Signs and symptoms of rheumatic diseases as first manifestation of pediatric cancer: diagnosis and prognosis implications. Rev Bras Reumatol Engl Ed. 2017; 57: 330 - 7. doi: 10.1016/j.rbre.2017.01.007

205. Alias A, Rodriguez EJ, Bateman HE, et al. Rheumatology and oncology: an updated review of rheumatic manifestations of malignancy and anti-neoplastictherapy. Bull NYU Hosp Jt Dis. 2012; 70: 109 - 14.

206. Grebenyuk V. et al. Fever of unknown origin: case reports from routine clinical practice and a review//Klinicka Mikrobiologie a Infekcni Lekarstvi. - 2021. - Т. 27. - N. 4. - С. 148 - 157.

207. Захарова И.Н., Османов И.М., Творогова Т.М., Горяйнова А.Н., Дмитриева Ю.А., Воробьева А.С., Короид Н.В. Длительная лихорадка у ребенка: в чем причина, как обследовать, лечить или не лечить? Медицинский совет. 2020; (10): 151 - 162. doi: 10.21518/2079-701X-2020-10-151-162.

208. Trapani S, Grisolia F, Simonini G, et al. Incidence of occult cancer in children presenting with musculoskeletal symptoms: a 10-year survey in a pediatric rheumatology unit. Semin Arthritis Rheum. 2000; 29: 348 - 59. doi: 10.1053/sarh.2000.5752

209. Li Q. et al. Quantifying the contribution of 18F-FDG PET to the diagnostic assessment of pediatric patients with fever of unknown origin: a systematic review and meta-analysis//Pediatric Radiology. - 2022. - С. 1 - 12.

210. JB. New imaging techniques in reumathology: MRI, scintigraphy and PET. Pol J Radiol. 2013; 78: 48 - 56. doi: 10.12659/PJR.889138

211. Colamussi P, Prandini N, Cittanti C, et al. Scintigraphy in rheumatic diseases. Best Pract Res Clin Rheumatol. 2004; 18: 909 - 26. doi: 10.1016/j.berh.2004.07.003

212. Handa R, Upadhyaya S, Kapoor S, et al. Tuberculosis and biologics in rheumatology: A special situation. Int J Rheum Dis. 2017; 20: 1313 - 25. doi: 10.1111/1756-185X.13129

213. Clemente D, Cuadros EN, Lovillo MC, et al. Position statement on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies, part 3: precautions in situations of surgery, fever, and opportunistic infections. Eur J Pediatr. 2023; 183: 915 - 27. doi: 10.1007/s00431-023-05295-4

214. Bovid KM, Moore MD. Juvenile Idiopathic Arthritis for the Pediatric Orthopedic Surgeon. Orthop Clin North Am. 2019; 50: 471 - 88. doi: 10.1016/j.ocl.2019.06.003

215. Radwan-Oczko M, I, Richards P, et al. Rheumatoid arthritis patients' oral health and disease activity. Int J Rheum Dis. 2019; 22: 1538 - 43. doi: 10.1111/1756-185X.13590

216. Lvovich S, Goldsmith DP. Neurological Complications of Rheumatic Disease. Semin Pediatr Neurol. 2017; 24: 54 - 9. doi: 10.1016/j.spen.2016.12.007

217. Shiari R. Neurologic manifestations of childhood rheumatic diseases. Iran J Child Neurol. 2012; 6: 1 - 7.

218. K, Trieschmann U, Leister N. und Analgosedierung diagnostische Eingriffe bei Kindern. AINS - · Intensivmed · Notfallmedizin · Schmerzther. 2023; 58: 409 - 20. doi: 10.1055/a-1925-7009

219. Dumas G, Arabi YM, Bartz R, et al. Diagnosis and management of autoimmune diseases in the ICU. Intensive Care Med. 2024; 50: 17 - 35. doi: 10.1007/s00134-023-07266-7

220. Janssen NM, Karnad DR, Guntupalli KK. Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome. Crit Care Clin. 2002; 18: 729 - 48. doi: 10.1016/S0749-0704(02)00025-8

221. Hynes L, Saetes S, McGuire B, et al. Child and Family Adaptation to Juvenile Idiopathic Arthritis - A Systematic Review of the Role of Resilience Resources and Mechanisms. Front Psychol. 2019; 10: 2445. doi: 10.3389/fpsyg.2019.02445

222. Frye WS, Milojevic D. The Role of Psychology in Pediatric Rheumatic Diseases. Pediatr Clin North Am. 2022; 69: 965 - 74. doi: 10.1016/j.pcl.2022.05.009

223. Chyzheuskaya I. et al. THU0508 Psychological features of children with rheumatic diseases. - 2017.

224. LeBovidge JS. Psychological Adjustment of Children and Adolescents WithChronic Arthritis: A Meta-analytic Review. J Pediatr Psychol. 2003; 28: 29 - 39. doi: 10.1093/jpepsy/28.1.29

225. Ferro MA, Boyle MH. Self-concept among youth with a chronic illness: A meta-analytic review. Health Psychol. 2013; 32: 839 - 48. doi: 10.1037/a0031861

226. Cousino MK, Hazen RA. Parenting Stress Among Caregivers of Children With Chronic Illness: A Systematic Review. J Pediatr Psychol. 2013; 38: 809 - 28. doi: 10.1093/jpepsy/jst049

227. Knafl K, Leeman J, Havill NL, et al. The Contribution of Parent and Family Variables to the Well-Being of Youth With Arthritis. J Fam Nurs. 2015; 21: 579 - 616. doi: 10.1177/1074840715601475

228. Kellgren, Jonas H. "The epidemiology of chronic rheumatism." Atlas of standard radiographs of arthritis 2 (1963): 22 - 23.

229. Bennett, Peter H. "Population studies of the rheumatic disease." Proceedings of the Third International Symposium. Excerpta Medica, 1968.

230. Dougados M, Linden SVD, Juhlin R, et al. The European Spondylarthropathy Study Group Preliminary Criteria for the Classification of Spondylarthropathy. Arthritis Rheum. 1991; 34: 1218 - 27. doi: 10.1002/art.1780341003

231. Amor, B et al. " de classification des spondylarthropathies" [Criteria of the classification of spondylarthropathies]. Revue du rhumatisme et des maladies osteo-articulaires vol. 57,2 (1990): 85 - 9.

232. , R. "Die juvenile Spondarthritis. Retrospektive Untersuchung an 71 Patienten" [Juvenile spondarthritis. Retrospective study of 71 patients]. Monatsschrift Kinderheilkunde: Organ der Deutschen Gesellschaft fur Kinderheilkunde vol. 135,1 (1987): 41 - 6.

233. Hussein A, Abdul-Khaliq H, Von Der Hardt H. Atypical spondyloarthritis in children: proposed diagnostic criteria. Eur J Pediatr. 1989; 148: 513 - 7. doi: 10.1007/BF00441545

234. Martini A, Ravelli A, Avcin T, et al. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol. 2019; 46: 190 - 7. doi: 10.3899/jrheum.180168

235. Henderson LA, Cron RQ. Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management. Paediatr Drugs. 2020; 22: 29 - 44. doi: 10.1007/s40272-019-00367-1

236. Ravelli A, S, Minoia F, et al. Macrophage Activation Syndrome. Hematol Oncol Clin North Am. 2015; 29: 927 - 41. doi: 10.1016/j.hoc.2015.06.010

237. Shakoory B, Geerlinks A, Wilejto M, et al. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis. 2023; 82: 1271 - 85. doi: 10.1136/ard-2023-224123

238. Hines MR, von Bahr Greenwood T, Beutel G, et al. Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults. Crit Care Med. 2022; 50: 860 - 72. doi: 10.1097/CCM.0000000000005361

239. Lehmberg K, Pink I, Eulenburg C, et al. Differentiating Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis from Other Forms of Hemophagocytic Lymphohistiocytosis. J Pediatr. 2013; 162: 1245 - 51. doi: 10.1016/j.jpeds.2012.11.081

240. Chen T-Y, Hsu M-H, Kuo H-C, et al. Outcome analysis of pediatric hemophagocytic lymphohistiocytosis. J Formos Med Assoc. 2021; 120: 172 - 9. doi: 10.1016/j.jfma.2020.03.025

241. Rigante D, Emmi G, Fastiggi M, et al. Macrophage activation syndrome in the course of monogenic autoinflammatory disorders. Clin Rheumatol. 2015; 34: 1333 - 9. doi: 10.1007/s10067-015-2923-0

242. Valade S, Mariotte E, Azoulay E. Coagulation Disorders in Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome. Crit Care Clin. 2020; 36: 415 - 26. doi: 10.1016/j.ccc.2019.12.004

243. Valade S, Azoulay E, Galicier L, et al. Coagulation Disorders and Bleedings in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis. Medicine (Baltimore). 2015; 94: e1692. doi: 10.1097/MD.0000000000001692

244. Iakunina LN, Plakhuta TG, Tsymbal IN. [State of hemostasis in hemorrhagic vasculitis in children]. Pediatriia. 1992; 16 - 20.

245. Law C, Raffini L. A Guide to the Use of Anticoagulant Drugs in Children. Pediatr Drugs. 2015; 17: 105 - 14. doi: 10.1007/s40272-015-0120-x

246. McGrowder, D., Brown, P., Gordon, L., Budall, S., Irving, R., Alexander-Lindo, R., & Mhlanga, M. The Application of Thromboelastography in Clinical Practice.

247. Xiang, L., Qian, J., Zhang, J., Ren, H., HU, X., LI, B., ... & NING, B. (2017). Clinical study of thromboelastography for assessment of coagulation disorders in children with sepsis. Chinese Journal of Emergency Medicine, 1284 - 1289.

248. Li Z, Xiao J, Song H, et al. Evaluation of coagulation disorders by thromboelastography in children with systemic lupus erythematosus. Lupus. 2019; 28: 181 - 8. doi: 10.1177/0961203318819137

249. T, Tse SML, Schneider R, et al. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr. 2006; 148: 683 - 6. doi: 10.1016/j.jpeds.2005.12.070

250. Bagri NK, Gupta L, Sen ES, et al. Macrophage Activation Syndrome in Children: Diagnosis and Management. Indian Pediatr. 2021; 58: 1155 - 61. doi: 10.1007/s13312-021-2399-8

251. Abolghasemi H, Shahverdi E, Niknam R, et al. Macrophage Activation Syndrome as the First Presentation of Juvenile Idiopathic Arthritis. IJBC. 2017; 9: 93 - 6.

252. Ansuini V, Rigante D, Esposito S. Debate around infection-dependent hemophagocytic syndrome in paediatrics. BMC Infect Dis. 2013; 13: 15. doi: 10.1186/1471-2334-13-15

253. D'Errico MM, Cuoco F, Biancardi C, et al. YIM-P58. Macrophage activation syndrome: the role of infectious triggers. Pediatr Rheumatol. 2014; 12: Y5. 1546-0096-12-S1-Y5. doi: 10.1186/1546-0096-12-S1-Y5

254. Eloseily EM, Cron RQ. Macrophage Activation Syndrome. In: Ragab G, Atkinson TP, Stoll ML, eds. The Microbiome in Rheumatic Diseases and Infection. Cham: Springer International Publishing 2018: 151 - 82.

255. Long S. S., Pickering L. K., Prober C. G. Principles and practice of pediatric infectious diseases. - 2023.

256. Xu D, Li S, Chen Z, et al. Detection of Mycoplasma pneumoniae in different respiratory specimens. Eur J Pediatr. 2011; 170: 851 - 8. doi: 10.1007/s00431-010-1360-y

257. Copete AR, Vera C, Herrera M, et al. Mycoplasma pneumoniae in Children With and Without Community-acquired Pneumonia. What do PCR and Serology Say? Pediatr Infect Dis J. 2020; 39: e104 - 8. doi: 10.1097/INF.0000000000002636

258. Waris ME, Toikka P, Saarinen T, et al. Diagnosis of Mycoplasma pneumoniae Pneumonia in Children. J Clin Microbiol. 1998; 36: 3155 - 9. doi: 10.1128/JCM.36.11.3155-3159.1998

259. Department of Microbiology, Maulana Azad Medical College, India, Kumar S, Kumar S, et al. Mycoplasma Pneumoniae as a Causative Agent of Community-Acquired Lower Respiratory Tract Infections in Children. Ann Pediatr Child Health. 2023; 11: 1 - 4. doi: 10.47739/2373-9312.pediatrics.1325

260. Blanche S, Caniglia M, Fischer A, et al. Epstein-Barr Virus-Associated Hemophagocytic Syndrome: Clinical Presentation and Treatment. Pediatr Hematol Oncol. 1989; 6: 233 - 5. doi: 10.3109/08880018909034292

261. Nowalk A, Green M. Epstein-Barr Virus. Microbiol Spectr. 2016; 4: 4.3.47. doi: 10.1128/microbiolspec.DMIH2-0011-2015

262. Zeng H-S, Xiong X-Y, Wei Y-D, et al. Macrophage activation syndrome in 13 children with systemic-onset juvenile idiopathic arthritis. World J Pediatr. 2008; 4: 97 - 101. doi: 10.1007/s12519-008-0018-6

263. Brisse E, Matthys P, Wouters CH. Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options. Br J Haematol. 2016; 174: 175 - 87. doi: 10.1111/bjh.14144

264. Lin C-I, Yu H-H, Lee J-H, et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol. 2012; 31: 1223 - 30. doi: 10.1007/s10067-012-1998-0

265. K, I, Z, et al. Systemic Juvenile Idiopathic Arthritis and Secondary Macrophage Activation Syndrome in Latvia from 2009 to 2020: A Nationwide Retrospective Study. Medicina (Mex). 2023; 59: 798. doi: 10.3390/medicina59040798

266. Nadimpalli S, Foca M, Satwani P, et al. Diagnostic yield of bronchoalveolar lavage in immunocompromised children with malignant and non-malignant disorders: BAL in Immunocompromised Children. Pediatr Pulmonol. 2017; 52: 820 - 6. doi: 10.1002/ppul.23644

267. Ers. Bronchoalveolar lavage in children. Eur Respir J. 2000; 15: 217 - 31. doi: 10.1183/09031936.00.15121700

268. Amanati A, Karimi A, Fahimzad A, et al. Prevalence of Human Herpes Viruses in Bronchoalveolar Lavage of Critically Ill Children Undergoing Mechanical Ventilation at a Pediatric Intensive Care Unit. Arch Pediatr Infect Dis. 2018; 6. doi: 10.5812/pedinfect.12685

269. Wong JCP, Hon KLE, Leung KKY, et al. Diagnostic Yield of Bronchoalveolar Lavage in Immunocompromised Children. J Trop Pediatr. 2021; 67: fmaa131. doi: 10.1093/tropej/fmaa131

270. Eroglu-Ertugrul NG, Yalcin E, Oguz B, et al. The value of flexible bronchoscopy in pulmonary infections of immunosuppressed children. Clin Respir J. 2020; 14: 78 - 84. doi: 10.1111/crj.13103

271. Gonski K, Cohn R, Widger J, et al. Utility of bronchoscopy in immunocompromised paediatric patients: Systematic review. Paediatr Respir Rev. 2020; 34: 24 - 34. doi: 10.1016/j.prrv.2020.02.003

272. S, Bayram S. [Investigation of Pneumocystis jirovecii pneumonia and colonization in iatrogenically immunosuppressed and immunocompetent patients]. Mikrobiyol Bul. 2015; 49: 221 - 30. doi: 10.5578/mb.9344

273. Lachant DJ, Croft DP, McGrane Minton H, et al. The clinical impact of pneumocystis and viral PCR testing on bronchoalveolar lavage in immunosuppressed patients. Respir Med. 2018; 145: 35 - 40. doi: 10.1016/j.rmed.2018.10.021

274. Stephan JL. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology. 2001; 40: 1285 - 92. doi: 10.1093/rheumatology/40.11.1285

275. Varadaraju S, Khandelwal P, Sankar J, et al. Multiple opportunistic infection-associated hemophagocytic lymphohistiocytosis in nephrotic syndrome: A case report. J Pediatr Crit Care. 2021; 8: 295. doi: 10.4103/jpcc.jpcc_64_21

276. Weyant RB, Kabbani D, Doucette K, et al. Pneumocystis jirovecii: a review with a focus on prevention and treatment. Expert Opin Pharmacother. 2021; 22: 1579 - 92. doi: 10.1080/14656566.2021.1915989

277. Morris A, Norris KA. Colonization by Pneumocystis jirovecii and Its Role in Disease. Clin Microbiol Rev. 2012; 25: 297 - 317. doi: 10.1128/CMR.00013-12

278. White PL, Price JS, Backx M. Pneumocystis jirovecii Pneumonia: Epidemiology, Clinical Manifestation and Diagnosis. Curr Fungal Infect Rep. 2019; 13: 260 - 73. doi: 10.1007/s12281-019-00349-3

279. M, M, J. Pneumocystis pneumonia in a child with sojia. Pediatr Rheumatol. 2014; 12: P225, 1546-0096-12-S1-P225. doi: 10.1186/1546-0096-12-S1-P225

280. Saper V. E. et al. Emergent high fatality lung disease in systemic juvenile arthritis//Annals of the rheumatic diseases. - 2019. - Т. 78. - N. 12. - С. 1722 - 1731.

281. Rayment JH, Narang I. Pulmonary Aspergillosis in a Previously Healthy 13-Year-Old Boy. Can Respir J. 2016; 2016: 4575942. doi: 10.1155/2016/4575942

282. de Mol M, de Jongste JC, van Westreenen M, et al. Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan: BAL Galactomannan Aspergillosis Children. Pediatr Pulmonol. 2013; 48: 789 - 96. doi: 10.1002/ppul.22670

283. Zhao M, Guan Y, Lin J, et al. Acute kidney injury in critical care: complications of hemophagocytic lymphohistiocytosis. Front Immunol. 2024; 15: 1396124. doi: 10.3389/fimmu.2024.1396124

284. Fitzgerald NE, MacClain KL. Imaging characteristics of hemophagocytic lymphohistiocytosis. Pediatr Radiol. 2003; 33: 392 - 401. doi: 10.1007/s00247-003-0894-9

285. Schmidt MH, Sung L, Shuckett BM. Hemophagocytic Lymphohistiocytosis in Children: Abdominal US Findings within 1 Week of Presentation. Radiology. 2004; 230: 685 - 9. doi: 10.1148/radiol.2303030223

286. Chinnici A, Beneforti L, Pegoraro F, et al. Approaching hemophagocytic lymphohistiocytosis. Front Immunol. 2023; 14: 1210041. doi: 10.3389/fimmu.2023.1210041

287. Malik P, Antonini L, Mannam P, et al. MRI Patterns in Pediatric CNS Hemophagocytic Lymphohistiocytosis. Am J Neuroradiol. 2021; 42: 2077 - 85. doi: 10.3174/ajnr.A7292

288. Shieh AC, Guler E, Smith DA, et al. Hemophagocytic Lymphohistiocytosis: A Primer for Radiologists. Am J Roentgenol. 2020; 214: W11 - 9. doi: 10.2214/AJR.19.21788

289. Hur M, Kim YC, Lee KM, et al. Macrophage Activation Syndrome in a Child with Systemic Juvenile Rheumatoid Arthritis. J Korean Med Sci. 2005; 20: 695. doi: 10.3346/jkms.2005.20.4.695

290. Behrens EM, Beukelman T, Paessler M, et al. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007; 34: 1133 - 8.

291. Shekarchian F, Abadi MKA, Shariati MM. Clinical approach to a child with hemophagocytic lymphohistiocytosis and bilateral optic nerve head infiltration: A case report and brief literature review. Clin Case Rep. 2023; 11: e7999. doi: 10.1002/ccr3.7999

292. Wang L, Suo L, Kou F, et al. Ocular Phenotypes in Patients With Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis in a Single Center Over 7 Years. Am J Ophthalmol. 2023; 253: 119 - 31. doi: 10.1016/j.ajo.2023.05.011

293. M. et al. Atypical eye manifestation in macrophage activation syndrome complicating systemic juvenile idiopathic arthritis//Alergia, Asma e . - 2020. - Т. 29. - N. 2. - С. 66 - 70.

294. Криулин И.А., Алексеева Е.И., Шилькрот И.Ю., Дворяковская Т.М. Вторичный гемофагоцитарный синдром: прогностическая модель и ранние маркеры развития у пациентов с системным ювенильным идиопатическим артритом. Результаты когортного ретроспективного исследования. Вопросы практической педиатрии. 2022; 17(6): 17 - 24. DOI: 10.20953/1817-7646-2022-6-17-24

295. Pan S, Yu H, Surti A, et al. Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. Br J Clin Pharmacol. 2019; 85: 1790 - 7. doi: 10.1111/bcp.13970

296. McAtee CL, Lubega J, Underbrink K, et al. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. JAMA Netw Open. 2021; 4: e2036321. doi: 10.1001/jamanetworkopen.2020.36321

297. Smolewska E, Cebula B, H, et al. Relationship between impaired apoptosis of lymphocytes and distribution of dendritic cells in peripheral blood and synovial fluid of children with juvenile idiopathic arthritis. Arch Immunol Ther Exp (Warsz). 2008; 56: 283 - 9. doi: 10.1007/s00005-008-0030-5

298. Hsin Y-C, Zhuang L-Z, Yeh K-W, et al. Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan. PloS One. 2015; 10: e0128768. doi: 10.1371/journal.pone.0128768

299. Бзарова Т., Алексеева Е., Акулова С. Случай эпштейна-барр вирусной инфекции, протекавшей под маской системного варианта ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2007; 6(3): 101 - 106.

300. S, Bayram S. Investigation of Pneumocystis jirovecii Pneumonia and Colonization in Iatrogenically Immunosuppressed and Immunocompetent Patients. Mikrobiyol Bul. 2015; 49: 221 - 30. doi: 10.5578/mb.9344

301. Bateman M, Oladele R, Kolls JK. Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches. Med Mycol. 2020; 58: 1015 - 28. doi: 10.1093/mmy/myaa024

302. Park JW, Curtis JR, Kim MJ, et al. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids - clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole. Arthritis Res Ther. 2019; 21: 207. doi: 10.1186/s13075-019-1996-6

303. Sulieman SE, Metjian TA, Zaoutis TE, et al. Pneumocystis Pneumonia: Epidemiology and Options for Prophylaxis in Non-HIV Immunocompromised Pediatric Patients. Curr Fungal Infect Rep. 2014; 8: 45 - 55. doi: 10.1007/s12281-014-0177-y

304. J, S, MT, et al. Pneumocystis jirovecii pneumonia in children. A retrospective study in a single center over three decades. Enfermedades Infecc Microbiol . 2020; 38: 111 - 8. doi: 10.1016/j.eimc.2019.05.005

305. Kim YW, Kwon BS, Lim SY, et al. Diagnostic value of bronchoalveolar lavage and bronchial washing in sputum-scarce or smear-negative cases with suspected pulmonary tuberculosis: a randomized study. Clin Microbiol Infect. 2020; 26: 911 - 6. doi: 10.1016/j.cmi.2019.11.013

306. Daelemans, Siel & Peeters, Linde & Wachter, Elke & Malfroot, Anne. (2019). Challenges in Diagnosing Mycobacterial Infections in Children. 21. 194 - 199.

307. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010; 36: 1185 - 206. doi: 10.1183/09031936.00028510

308. Qu Y, Liu M, Sun X, et al. Development and evaluation of a triplex droplet digital PCR method for differentiation of M. tuberculosis, M. bovis and BCG. Front Microbiol. 2024; 15: 1397792. doi: 10.3389/fmicb.2024.1397792

309. Bal ZS, Yazici P, Sen S, et al. A fatal case of tuberculous meningitis in a child with juvenile idiopathic arthritis: a diagnostic challenge. Rev Soc Bras Med Trop. 2017; 50: 709 - 11. doi: 10.1590/0037-8682-0410-2016

310. Noguera-Julian A, J, Brinkmann F, et al. Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study. Clin Infect Dis. 2020; 71: 2561 - 9. doi: 10.1093/cid/ciz1138

311. Restrepo-Gualteros SM, Gutierrez MJ, Villamil-Osorio M, et al. Challenges and Clinical Implications of the Diagnosis of Cytomegalovirus Lung Infection in Children. Curr Infect Dis Rep. 2019; 21: 24. doi: 10.1007/s11908-019-0681-x

312. Lyu J, Deng Q, Li R, et al. Pneumonia Caused by Coinfection with Cytomegalovirus and Pneumocystis jirovecii in an HIV-Negative Infant Diagnosed by Metagenomic Next-Generation Sequencing. Infect Drug Resist. 2022; Volume 15: 3417 - 25. doi: 10.2147/IDR.S364241

313. Ramos JT, Romero CA, Belda S, et al. Clinical practice update of antifungal prophylaxis in immunocompromised children. Rev Espanola Quimioter Publicacion Of Soc Espanola Quimioter 2019; 32: 410 - 25.

314. Tragiannidis A, Kyriakidis I, I, et al. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha inhibitors. Mycoses. 2017; 60: 222 - 9. doi: 10.1111/myc.12576

315. Sandau KE, Funk M, Auerbach A, et al. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. Circulation. 2017; 136. doi: 10.1161/CIR.0000000000000527

316. Lazzerini PE, Capecchi PL, Guideri F, et al. Comparison of Frequency of Complex Ventricular Arrhythmias in Patients With Positive Versus Negative Anti-Ro/SSA and Connective Tissue Disease. Am J Cardiol. 2007; 100: 1029 - 34. doi: 10.1016/j.amjcard.2007.04.048

317. Caforio ALP, Adler Y, Agostini C, et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur Heart J. 2017; 38: 2649 - 62. doi: 10.1093/eurheartj/ehx321

318. Malattia C, Tzaribachev N, van den Berg JM, et al. Juvenile idiopathic arthritis - the role of imaging from a rheumatologist's perspective. Pediatr Radiol. 2018; 48: 785 - 91. doi: 10.1007/s00247-017-4014-7

319. Malattia C, Tolend M, Mazzoni M, et al. Current status of MR imaging of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2020; 34: 101629. doi: 10.1016/j.berh.2020.101629

320. Zhang P, Li X, Li Y, et al. Reversible posterior leukoencephalopathy syndrome secondary to systemic-onset juvenile idiopathic arthritis: A case report and review of the literature. Biomed Rep. 2015; 3: 55 - 8. doi: 10.3892/br.2014.380

321. Koenig MK, Perez M, Rothenberg S, et al. Juvenile Onset Central Nervous System Folate Deficiency and Rheumatoid Arthritis. J Child Neurol. 2008; 23: 106 - 7. doi: 10.1177/0883073807307986

322. AN, C, R, et al. Concurrence of juvenile idiopathic arthritis and primary demyelinating disease in a young child. Mult Scler Relat Disord. 2019; 27: 20 - 2. doi: 10.1016/j.msard.2018.10.002

323. DMR, Buscatti IM, B, et al. Neurite em paciente com artrite juvenil. Rev Bras Reumatol. 2014; 54: 486 - 9. doi: 10.1016/j.rbr.2014.01.011

324. Weng Y, Yi C, Liang H, et al. The Brain Structural-Functional Vulnerability in Drug-Naive Children With Juvenile Idiopathic Arthritis: Insights From the Hippocampus. Front Hum Neurosci. 2022; 16: 833602. doi: 10.3389/fnhum.2022.833602

325. Mavrogeni S, Koutsogeorgopoulou L, Dimitroulas T, et al. Combined Brain/Heart Magnetic Resonance Imaging in Systemic Lupus Erythematosus. Curr Cardiol Rev. 2020; 16: 178 - 86. doi: 10.2174/1573403X15666190801122105

326. Zajaczkowska M, Papierkowski A, Szczepanowska A, et al. [Influence of glucocorticoid steroid therapy on gastric and duodenal mucosa and Helicobacter pylori infection in children with nephrotic syndrome]. Pol Merkur Lek Organ Pol Tow Lek. 2001; 10: 165 - 7.

327. Galindo-Zavala R, Bou-Torrent R, B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol Online J. 2020; 18: 20. doi: 10.1186/s12969-020-0411-9

328. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: ACR guideline for glucocorticoid-induced osteoporosis prevention and treatment. Arthritis Rheumatol. 2017; 69: 1521 - 37. doi: 10.1002/art.40137

329. Harari S, Paciocco G, Aramu S. Ear and nose involvement in systemic diseases. Monaldi Arch Chest Dis Arch Monaldi Mal Torace. 2000; 55: 466 - 70.

330. Stoustrup P, Resnick CM, Abramowicz S, et al. Management of Orofacial Manifestations of Juvenile Idiopathic Arthritis: Interdisciplinary Consensus-Based Recommendations. Arthritis Rheumatol. 2023; 75: 4 - 14. doi: 10.1002/art.42338

331. Walton AG, Welbury RR, Thomason JM, et al. Oral health and juvenile idiopathic arthritis: a review. Rheumatology. 2000; 39: 550 - 5. doi: 10.1093/rheumatology/39.5.550

332. Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care Res. 2019; 71: 703 - 16. doi: 10.1002/acr.23871

333. Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018; 77: 1107 - 17. doi: 10.1136/annrheumdis-2018-213131

334. Arsenaki E, Georgakopoulos P, Mitropoulou P, et al. Cardiovascular Disease in Juvenile Idiopathic Arthritis. Curr Vasc Pharmacol. 2020; 18: 580 - 91. doi: 10.2174/1570161118666200408121307

335. Hou J, Song FY, Xu YJ, et al. [Analysis of 13 cases with pediatric rheumatic disease combined with endocrine disorder]. Zhonghua Er Ke Za Zhi Chin J Pediatr. 2021; 59: 865 - 70. doi: 10.3760/cma.j.cn112140-20210303-00178

336. Whittle, Vanessa & Gane, J & Cheetham, T. (2017). G169(P) Management of steroid induced diabetes in children: A national perspective. Archives of Disease in Childhood. 102. A69.1-A69.10.1136/archdischild-2017-313087.168.

337. Hsieh L-F, Mao H-F, Lu C-C, et al. 31 - Rheumatologic Rehabilitation. In: Cifu DX, ed. Braddom's Physical Medicine and Rehabilitation (Sixth Edition). Philadelphia: Elsevier 2021: 606 - 626.e1.

338. Prothero L, Barley E, Galloway J, et al. The evidence base for psychological interventions for rheumatoid arthritis: A systematic review of reviews. Int J Nurs Stud. 2018; 82: 20 - 9. doi: 10.1016/j.ijnurstu.2018.03.008

339. Sestan M, Grguric D, Sedmak M, et al. Quality of life in children suffering from juvenile idiopathic arthritis-associated uveitis. Rheumatol Int. 2020; 40: 1117 - 21. doi: 10.1007/s00296-020-04536-1

340. Berntson L. A pilot study of possible anti-inflammatory effects of the specific carbohydrate diet in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2021; 19: 88. doi: 10.1186/s12969-021-00577-3

341. Caetano MC, Ortiz TT, Terreri MTSRLA, et al. Inadequate dietary intake of children and adolescents with juvenile idiopathic arthritis and systemic lupus erythematosus. J Pediatr (Rio J). 2009; 85: 509 - 15. doi: 10.2223/JPED.1941

342. Fc A. The Portuguese Society of Rheumatology position paper on the use of biosimilars - 2017 update. 2017.

343. Atzeni F, Sebastiani M, Ricci C, et al. Position paper of Italian rheumatologists on the use of biosimilar drugs.

344. Abad , Andreu JL, Caracuel Ruiz , et al. Position Paper From the Spanish Society of Rheumatology on Biosimilar Drugs. Reumatol Engl Ed. 2015; 11: 269 - 78. doi: 10.1016/j.reumae.2015.03.012

345. Huizinga TWJ, Torii Y, Muniz R. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. Rheumatol Ther. 2021; 8: 41 - 61. doi: 10.1007/s40744-020-00259-8

346. Lim LSH, Lokku A, Pullenayegum E, et al. Probability of Response in the First Sixteen Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials. Arthritis Care Res. 2023; acr.25003. doi: 10.1002/acr.25003

347. Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018; 77: 819 - 28. doi: 10.1136/annrheumdis-2018-213030

348. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res. 2019; 71: 717 - 34. doi: 10.1002/acr.23870

349. Shi C-L, Zhang Y, Zhang Z-Y, et al. Comparative Efficacy and Safety of Non-Steroidal Anti-Inflammatory Drugs in Patients With Juvenile Idiopathic Arthritis: A Systematic Review and Network Meta-analysis. Indian Pediatr. 2021; 58: 162 - 8.

350. Levy DM, Imundo LF. Nonsteroidal Anti-Inflammatory Drugs: A survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data. Pediatr Rheumatol. 2010; 8: 7. doi: 10.1186/1546-0096-8-7

351. Litalien C., Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children//Paediatric drugs. - 2001. - Т. 3. - N. 11. - С. 817 - 858.

352. Hollingworth P. The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases//Rheumatology. - 1993. - Т. 32. - N. 1. - С. 73 - 77.

353. Guillaume-Czitrom S. Les anti-inflammatoires non dans les rhumatismes inflammatoires chroniques de l'enfant [Non-steroidal anti-inflammatory drugs in chronic inflammatory arthritis in children]. La Lettre du Rhumatologue N 379 - 380 - 2012.

354. Gupta P, Sachdev HP. Safety of oral use of nimesulide in children: systematic review of randomized controlled trials. Indian Pediatr. 2003 Jun; 40(6): 518 - 31. PMID: 12824661.

355. Todd PA, Sorkin EM. Diclofenac Sodium: A Reappraisal of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy. Drugs. 1988; 35: 244 - 85. doi: 10.2165/00003495-198835030-00004

356. Алексеева Е., Бзарова Т. Алгоритм диагностики и лечения ювенильного артрита. Вопросы современной педиатрии. 2010; 9(6): 78 - 104.

357. Standing J.F. Diclofenac for acute pain in children: Pharmacokinetics and safety. - University of London, University College London (United Kingdom), 2007.

358. Petty RE, Laxer RM, Lindsley CB, et al. Textbook of pediatric rheumatology. 8th ed. Philadelphia: Elsevier, Inc 2020.

359. Levy DM, Imundo LF. Nonsteroidal Anti-Inflammatory Drugs: A survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data. Pediatr Rheumatol. 2010; 8: 7. doi: 10.1186/1546-0096-8-7

360. Litalien C., Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children//Paediatric drugs. - 2001. - Т. 3. - N. 11. - С. 817 - 858.

361. Hollingworth P. The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases//Rheumatology. - 1993. - Т. 32. - N. 1. - С. 73 - 77.

362. Guillaume-Czitrom S. Les anti-inflammatoires non dans les rhumatismes inflammatoires chroniques de l'enfant [Non-steroidal anti-inflammatory drugs in chronic inflammatory arthritis in children]. La Lettre du Rhumatologue N 379 - 380 - 2012.

363. Gupta P, Sachdev HP. Safety of oral use of nimesulide in children: systematic review of randomized controlled trials. Indian Pediatr. 2003 Jun; 40(6): 518 - 31. PMID: 12824661.

364. Алексеева Е., Валиева С. Оценка эффективности, переносимости и безопасности нимесулида у детей с ювенильным артритом. Вопросы современной педиатрии. 2007; 6(6): 76 - 80.

365. Zulian F, Martini G, Gobber D, et al. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatol Oxf Engl. 2003; 42: 1254 - 9. doi: 10.1093/rheumatology/keg358

366. https://neo.barnlakarforeningen.se/wp-content/uploads/sites/11/2015/05/Medical-treatment-of-juvenile-idiopathic-arthritis.pdf.

367. Rubin S, Ohana O, Goldberg O, et al. The efficacy and safety of intra-articular injection of triamcinolone acetonide versus triamcinolone hexacetonide for treatment of juvenile idiopathic arthritis. Pediatr Rheumatol. 2022; 20: 5. doi: 10.1186/s12969-022-00666-x

368. Zulian F. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology. 2004; 43: 1288 - 91. doi: 10.1093/rheumatology/keh313

369. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum. 2006; 54: 1401 - 9. doi: 10.1002/art.21796

370. Scherer J, Rainsford KD, Kean CA, et al. Pharmacology of intra-articular triamcinolone. Inflammopharmacology. 2014; 22: 201 - 17. doi: 10.1007/s10787-014-0205-0

371. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011; 63: 465 - 82. doi: 10.1002/acr.20460

372. Onel K, Rumsey DG, Shenoi S. Juvenile Idiopathic Arthritis Treatment Updates. Rheum Dis Clin N Am. 2021; 47: 545 - 63. doi: 10.1016/j.rdc.2021.07.009

373. Schiappapietra B, Varnier G, Rosina S, et al. Glucocorticoids in Juvenile Idiopathic Arthritis. Neuroimmunomodulation. 2015; 22: 112 - 8. doi: 10.1159/000362732

374. Nasef S. Juvenile Idiopathic Arthritis: An Overview for the Clinicians. Suez Canal Univ Med J. 2021; 24: 93 - 103. doi: 10.21608/scumj.2021.192012

375. Batu ED. Glucocorticoid treatment in juvenile idiopathic arthritis. Rheumatol Int. 2019; 39: 13 - 27. doi: 10.1007/s00296-018-4168-0

376. Ravelli A, S, Bracciolini G, et al. Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet Lond Engl. 2017; 389: 909 - 16. doi: 10.1016/S0140-6736(17)30065-X

377. Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018; 16: 46. doi: 10.1186/s12969-018-0255-8

378. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000; 43: 1849 - 57. doi: 10.1002/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO; 2-F

379. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50: 2191 - 201. doi: 10.1002/art.20288

380. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in Resistant Juvenile Rheumatoid Arthritis: Results of the U.S.A. - U.S.S.R. Double-Blind, Placebo-Controlled Trial. N Engl J Med. 1992; 326: 1043 - 9. doi: 10.1056/NEJM199204163261602

381. Ravelli, A., Migliavacca, D., Viola, S., Ruperto, N., Pistorio, A., & Martini, A. (1999). Efficacy of folinic arid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clinical and experimental rheumatology, 17, 625 - 627.

382. LRI Children's Hospital Paediatric Rheumatology Methotrexate therapy/url https://secure.library.leicestershospitals.nhs.uk/PAGL/Shared%20Documents/Methotrexate%20Therapy%20in%20Paediatric%20Rheumatology%20UHL%20Childrens%20Hospital%20Guideline.pdf.

383. Niehues T, Lankisch P. Recommendations for the Use of Methotrexate in Juvenile Idiopathic Arthritis: Pediatr Drugs. 2006; 8: 347 - 56. doi: 10.2165/00148581-200608060-00003

384. Calvo I, J, Robledillo JC, et al. Recomendaciones para el uso de metotrexato en pacientes con artritis juvenil. An . 2016; 84: 177.e1 - 177.e8. doi: 10.1016/j.anpedi.2015.05.005

385. Silverman E, Spiegel L, Hawkins D, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2005; 52: 554 - 62. doi: 10.1002/art.20861

386. Foeldvari I, Wierk A. Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol. 2010; 37: 1763 - 7. doi: 10.3899/jrheum.090874

387. Shepherd J, Cooper K, Harris P, et al. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess Winch Engl. 2016; 20: 1 - 222. doi: 10.3310/hta20340

388. Brunner HI, Ruperto N, Tzaribachev N, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018; 77: 21 - 9. doi: 10.1136/annrheumdis-2016-210456

389. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013; 72: 517 - 24. doi: 10.1136/annrheumdis-2011-201244

390. Foeldvari I, Constantin T, J, et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis Res Ther. 2019; 21: 125. doi: 10.1186/s13075-019-1916-9

391. Ruperto N, Brunner HI, Ramanan AV, et al. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatol Oxf Engl. 2021; 60: 4568 - 80. doi: 10.1093/rheumatology/keab047

392. Ruperto N, Brunner HI, Synoverska O, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet Lond Engl. 2021; 398: 1984 - 96. doi: 10.1016/S0140-6736(21) 01255-1

393. Burrone M, Mazzoni M, Naddei R, et al. Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trial. Pediatr Rheumatol. 2022; 20: 80. doi: 10.1186/s12969-022-00739-x

394. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000; 342: 763 - 9. doi: 10.1056/NEJM200003163421103

395. A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis. https://ClinicalTrials.gov/show/NCT03725007.

396. Juhl CB, Cagnotto G, F, et al. TNF-alpha inhibitors for juvenile idiopathic arthritis. Cochrane Database Syst Rev. Published Online First: 28 August 2020. doi: 10.1002/14651858.CD013715

397. Yamaoka K, Oku K. JAK inhibitors in rheumatology. Immunol Med. 2023; 1 - 10. doi: 10.1080/25785826.2023.2172808

398. Conaghan PG, Mysler E, Tanaka Y, et al. Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program. Drug Saf. 2021; 44: 515 - 30. doi: 10.1007/s40264-020-01036-w

399. A, Horneff G. Januskinase-Inhibitoren in der Kinderrheumatologie: Janus kinase inhibitors in pediatric rheumatology. Arthritis Rheuma. 2021; 41: 137 - 47. doi: 10.1055/a-1400-4468

400. van Vollenhoven R, Hall S, Wells AF, et al. AB0333 Sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2022; 81: 1290 - 1. doi: 10.1136/annrheumdis-2022-eular.1191

401. Fantus SA, Ruderman EM. Updates in the Treatment of Rheumatoid Arthritis. Curr Treat Options Rheumatol. 2021; 7: 99 - 111. doi: 10.1007/s40674-021-00173-2

402. Алексеева Е.И., Крехова Е.А., Криулин И.А., Криулина Т.Ю., Дворяковская Т.М., Исаева К.Б., Чистякова Е.Г., Чомахидзе А.М., Ломакина О.Л., Фетисова А.Н., Чибисова К.В., Цулукия И.Т., Шингарова М.Ш., Ботова М.С., Кондратьева Н.М., Кокина М.Ю., Румянцев М.А. Опыт применения ингибитора янус-киназ упадацитиниба у детей с ревматическими болезнями. Вопросы практической педиатрии. 2024; 19(2): 59 - 79. DOI: 10.20953/1817-7646-2024-2-59-79.

403. Anink J, Otten MH, Prince FHM, et al. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register. Rheumatol Oxf Engl. 2013; 52: 712 - 7. doi: 10.1093/rheumatology/kes373

404. Bergman M, Patel P, Chen N, et al. Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States. Rheumatol Ther. 2021; 8: 109 - 18. doi: 10.1007/s40744-020-00256-x

405. Yue X, Huang B, Hincapie AL, et al. Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA. Rheumatology. 2021; 60: 4063 - 73. doi: 10.1093/rheumatology/keaa877

406. Галстян Л.А., Жолобова Е.С., Сучкова Д.В., Чебышева С.Н., Мелешкина А.В. Опыт эффективного долговременного применения адалимумаба в лечении пациента с ранним дебютом ювенильного идиопатического артрита и увеита//Педиатрия. Consilium Medicum. - 2020. - N 2. - С. 67 - 71. doi: 10.26442/26586630.2020.2.200233

407. Fernandez JM, Madsen S, Krase JM, et al. Classification and mitigation of negative injection experiences with biologic medications. Dermatol Ther. 2020; 33: e13240. doi: 10.1111/dth.13240

408. Инструкция по применению лекарственного препарата Энбрел ЛП-0021220931121.

409. Инструкция по применению лекарственного препарата Этанерцепт ПСК ЛП-007057-310521.

410. Инструкция по применению лекарственного препарата Эрелзи ЛП-006650-141220.

411. Инструкция по применению лекарственного препарата Энбрел ЛСР-006652/09-050315 с Изменениями N 3.

412. Письмо ФАС от 22.12.2021 N ТН/109573/21 "О формировании документации на закупку лекарственных препаратов с МНН "Этанерцепт."

413. Houlton S. Benefits and drawbacks of moving to biosimilar medicines. Prescriber. 2019; 30: 13 - 5. doi: 10.1002/psb.1773

414. Horneff G, Klein A, Klotsche J, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016; 18: 272. doi: 10.1186/s13075-016-1170-3

415. Prabu N, Petciappan V, Anand G, et al. AB1250 Tofacitinib is a safe and effective treatment option for juvenile idiopathic arthritis. Ann Rheum Dis. 2022; 81: 1735.4 - 1736. doi: 10.1136/annrheumdis-2022-eular.3173

416. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. The Lancet. 2008; 372: 383 - 91. doi: 10.1016/S0140-6736(08)60998-8

417. Kaegi C, Wuest B, Schreiner J, et al. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front Immunol. 2019; 10: 1990. doi: 10.3389/fimmu.2019.01990

418. Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011; 30: 1163 - 72. doi: 10.1007/s10067-011-1720-7

419. Kearsley-Fleet L, Sampath S, McCann LJ, et al. Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom. Rheumatol Oxf Engl. 2019; 58: 331 - 5. doi: 10.1093/rheumatology/key306

420. Sakamoto AP, Pinheiro MM, Barbosa CMPL, et al. Uso de rituximabe em adultos jovens com de artrite juvenil ao tratamento convencional: relato de 6 casos. Rev Bras Reumatol. 2015; 55: 536 - 41. doi: 10.1016/j.rbr.2014.12.015

421. Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. The Lancet. 2018; 391: 2513 - 24. doi: 10.1016/S0140-6736(18) 31116-4

422. Foster HE, Minden K, Clemente D, et al. EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Ann Rheum Dis. 2017; 76: 639 - 46. doi: 10.1136/annrheumdis-2016-210112

423. Magnani A, Pistorio A, Magni-Manzoni S, et al. Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol. 2009; 36: 628 - 34. doi: 10.3899/jrheum.080560

424. Kaplan MM, Kurt T, Polat MC, et al. Predictors of relapse in patients with oligoarticular juvenile idiopathic arthritis in remission off medication. Eur J Pediatr. 2023; 182: 4557 - 64. doi: 10.1007/s00431-023-05123-9

425. Barbar-Smiley, F., Cooper, A., Edelheit, B., Flanagan, E., Gillespie-Taylor, M., Hays, K., ... & Veiga, K. SUPPLEMENTARY APPENDIX 3: Evidence Report 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis (JIA): Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint (TMJ) Arthritis and Systemic JIA.

426. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2022; 74: 553 - 69. doi: 10.1002/art.42037

427. Crayne CB, Beukelman T. Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis. Pediatr Clin North Am. 2018; 65: 657 - 74. doi: 10.1016/j.pcl.2018.03.005

428. V, M, MY, et al. What is the impact of methotrexate on liver in patients with juvenile idiopathic arthritis? Results of liver SWE performed in a single centre. Mod Rheumatol. 2022; 32: 776 - 82. doi: 10.1093/mr/roab064

429. van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001; 44: 1515 - 24. doi: 10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO; 2 - 7

430. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2022; 74: 553 - 69. doi: 10.1002/art.42037

431. Herlin T. Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis. Core Evid. 2009; 181. doi: 10.2147/CE.S5992

432. Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2012; 22: 109 - 15. doi: 10.3109/s10165-011-0481-0

433. Dubko M, Kalashnikova O, Kostik M, et al. AB0554 Abatacept (ORENCIA): Experience of practical application. Ann Rheum Dis. 2013; 71: 670.3 - 670. doi: 10.1136/annrheumdis-2012-eular.554

434. Choi JY, Chung JE, Park JH, et al. Surveillance of adverse drug events associated with etanercept prescribed for juvenile idiopathic arthritis in a single center up to 9-years: A retrospective observational study. PLOS ONE. 2018; 13: e0204573. doi: 10.1371/journal.pone.0204573

435. Ayaz NA, , R, et al. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study. Rheumatol Int. 2020; 40: 1111 - 6. doi: 10.1007/s00296-020-04596-3

436. Walscheid K, Glandorf K, Rothaus K, et al. Enthesitis-related Arthritis: Prevalence and Complications of Associated Uveitis in Children and Adolescents From a Population-based Nationwide Study in Germany. J Rheumatol. 2021; 48: 262 - 9. doi: 10.3899/jrheum.191085

437. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2016; 68: 282 - 98. doi: 10.1002/art.39298

438. Burgos-Vargas R. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002; 61: 941 - 2. doi: 10.1136/ard.61.10.941

439. Van Rossum MAJ, Van Soesbergen RM, Boers M, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis. 2007; 66: 1518 - 24. doi: 10.1136/ard.2006.064717

440. Brooks CD. Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol. 2001; 28: 845 - 53.

441. Gmuca S, Weiss PF. Evaluation and Treatment of Childhood Enthesitis-Related Arthritis. Curr Treat Options Rheumatol. 2015; 1: 350 - 64. doi: 10.1007/s40674-015-0027-2

442. Weiss PF, Xiao R, Brandon TG, et al. Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis. J Rheumatol. 2018; 45: 107 - 14. doi: 10.3899/jrheum.170251

443. Windschall D, Muller T, Becker I, et al. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis. Clin Rheumatol. 2015; 34: 61 - 9. doi: 10.1007/s10067-014-2744-6

444. Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014; 73: 1114 - 22. doi: 10.1136/annrheumdis-2012-203046

445. Minden K, Niewerth M, Zink A, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology. 2012; 51: 1407 - 15. doi: 10.1093/rheumatology/kes019

446. Batthish M, Rachlis A, Wong B, et al. Intra-rater reliability of the bath ankylosing spondylitis disease activity index (BASDAI) and the bath ankylosing spondylitis functional index (BASFI) in children with spondyloarthritis. Pediatr Rheumatol. 2012; 10: A45, 1546-0096-10-S1-A45. doi: 10.1186/1546-0096-10-S1-A45

447. Berard RA, Laxer RM. Learning the hard way: clinical trials in juvenile idiopathic arthritis. Ann Rheum Dis. 2018; 77: 1 - 2. doi: 10.1136/annrheumdis-2017-211108

448. Burgos-Vargas R, Tse SML, Horneff G, et al. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis. Arthritis Care Res. 2015; 67: 1503 - 12. doi: 10.1002/acr.22657

449. Horneff G, Fitter S, Foeldvari I, et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther. 2012; 14: R230. doi: 10.1186/ar4072

450. Horneff G, Foeldvari I, Minden K, et al. Efficacy and Safety of Etanercept in Patients With the Enthesitis-Related Arthritis Category of Juvenile Idiopathic Arthritis: Results From a Phase III Randomized, Double-Blind Study. Arthritis Rheumatol. 2015; 67: 2240 - 9. doi: 10.1002/art.39145

451. Inman RD, Davis JC, Heijde DVD, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008; 58: 3402 - 12. doi: 10.1002/art.23969

452. Baer J, Klotsche J, Foeldvari I. Secukinumab in the treatment for patients with juvenile enthesitis related arthritis non-responsive to anti-TNF treatment according the Juvenile Spondyloarthritis Disease Activity Index. Pathog Rheum Arthritis One Year Rev 2022. 2022; 40: 620 - 4. doi: 10.55563/clinexprheumatol/1u8y08

453. Brunner HI, Foeldvari I, Alexeeva E, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis. 2023; 82: 154 - 60. doi: 10.1136/ard-2022-222849

454. Wu P, Huang C, Liao P, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis. Int J Rheum Dis. 2023; 26: 2119 - 21. doi: 10.1111/1756-185X.14845

455. Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021; 80: 1004 - 13. doi: 10.1136/annrheumdis-2020-219601

456. Van Der Heijde D, Song I-H, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. The Lancet. 2019; 394: 2108 - 17. doi: 10.1016/S0140-6736(19) 32534-6

457. Bou R, A, F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int. 2015; 35: 777 - 85. doi: 10.1007/s00296-015-3231-3

458. Foeldvari I., Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis//The Journal of rheumatology. - 2005. - Т. 32. - N. 2. - С. 362 - 365.

459. Heiligenhaus A, Mingels A, Heinz C, et al. Methotrexate for Uveitis Associated with Juvenile Idiopathic Arthritis: Value and Requirement for Additional Anti-Inflammatory Medication. Eur J Ophthalmol. 2007; 17: 743 - 8. doi: 10.1177/112067210701700509

460. Oray M., . Treatment of juvenile idiopathic arthritis-associated uveitis//Turkish Journal of Ophthalmology. - 2016. - Т. 46. - N. 2. - С. 77.

461. Tappeiner C, Roesel M, Heinz C, et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye Lond Engl. 2009; 23: 1192 - 8. doi: 10.1038/eye.2008.174

462. Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010; 149: 423 - 432.e1 - 2. doi: 10.1016/j.ajo.2009.09.026

463. Sen E.S., Ramanan A.V. Juvenile idiopathic arthritis-associated uveitis//Clinical Immunology. - 2020. - Т. 211. - С. 108322.

464. Horton S, Jones AP, Guly CM, et al. Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE Trial. Am J Ophthalmol. 2019; 207: 170 - 4. doi: 10.1016/j.ajo.2019.06.007

465. Lanz S, Seidel G, Skrabl-Baumgartner A. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab. Pediatr Rheumatol. 2021; 19: 132. doi: 10.1186/s12969-021-00630-1

466. Ramanan A. V. et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial//The Lancet Rheumatology. - 2020. - Т. 2. - N. 3. - С. e135 - e141.

467. Babu K, Mooss V, Rao A. Tofacitinib in juvenile idiopathic arthritis-associated uveitis. Indian J Ophthalmol - Case Rep. 2022; 2: 911. doi: 10.4103/ijo.IJO_789_22

468. Chen JL, Abiri P, Tsui E. Recent advances in the treatment of juvenile idiopathic arthritis-associated uveitis. Ther Adv Ophthalmol. 2021; 13: 251584142098457. doi: 10.1177/2515841420984572

469. Thomas J, Kuthyar S, Shantha JG, et al. Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis. Ann Eye Sci. 2021; 6: 19 - 19. doi: 10.21037/aes-2019-dmu-10

470. Kenawy N, Cleary G, Mewar D, et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2011; 249: 297 - 300. doi: 10.1007/s00417-010-1523-6

471. AC de C, Leite CAC, Leite ACRM, et al. A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis. J Rheumatol. 2014; 41: 338 - 44. doi: 10.3899/jrheum.130294

472. Jahan A, Dewan V, Yadav TP. Leflunomide in systemic onset Juvenile idiopathic arthritis. Indian Pediatr. 2012; 49: 750 - 2. doi: 10.1007/s13312-012-0139-9

473. Oray M, . Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Turk J Ophthalmol. 2016; 46: 77 - 82. doi: 10.4274/tjo.09581

474. Doycheva D. et al. Mycophenolate mofetil in the treatment of uveitis in children//British journal of ophthalmology. - 2007. - Т. 91. - N. 2. - С. 180 - 184.

475. Baquet-Walscheid K, Heinz C, Rath T, et al. Beneficial Effect of Upadacitinib in an Adult Patient with Juvenile Idiopathic Arthritis-associated Uveitis after Unsatisfactory Response to Tofacitinib: A Case Report. Ocul Immunol Inflamm. 2022; 1 - 2. doi: 10.1080/09273948.2022.2069128

476. Tappeiner C, Miserocchi E, Bodaghi B, et al. Abatacept in the Treatment of Severe, Longstanding, and Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. J Rheumatol. 2015; 42: 706 - 11. doi: 10.3899/jrheum.140410

477. Ravelli A, Davi S, Minoia F, et al. Macrophage Activation Syndrome. Hematol Oncol Clin North Am. 2015; 29: 927 - 41. doi: 10.1016/j.hoc.2015.06.010

478. Henter J-I. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002; 100: 2367 - 73. doi: 10.1182/blood-2002-01-0172

479. La P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019; 133: 2465 - 77. doi: 10.1182/blood.2018894618

480. Stephan J.L. et al. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients//Rheumatology. - 2001. - Т. 40. - N. 11. - С. 1285 - 1292.

481. I.A. Kriulin IAK, Kriulin IA, National Medical Research Center for Children's Health, Moscow, Russian Federation, et al. Hemophagocytic lymphohistiocytosis: mechanisms of development, clinical manifestations, and treatments. Vopr Prakt Pediatr. 2021; 16: 94 - 102. doi: 10.20953/1817-7646-2021-6-94-102

482. Ramanan A.V., Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis//The Journal of rheumatology. - 2003. - Т. 30. - N. 2. - С. 401 - 403.

483. Bruck N. et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids//JCR: Journal of Clinical Rheumatology. - 2011. - Т. 17. - N. 1. - С. 23 - 27.

484. Zhang H, Yang S-W, Fu Y-C, et al. Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis. Immunol Res. 2022; 70: 566 - 77. doi: 10.1007/s12026-022-09285-w

485. Криулин И.А., Алексеева Е.И., Шилькрот И.Ю., Дворяковская Т.М. Лечение вторичного гемофагоцитарного синдрома у пациентов с системным ювенильным идиопатическим артритом. Результаты когортного ретроспективного исследования. Вопросы практической педиатрии. 2022; 17(5): 7 - 19. DOI: 10.20953/1817-7646-2022-5-7-19.

486. Pelewicz K, P. Glucocorticoid Withdrawal-An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice. Diagnostics. 2021; 11: 728. doi: 10.3390/diagnostics11040728

487. Alves C, Robazzi TCV, Mendon&ccedil; a M. Withdrawal from glucocorticosteroid therapy: clinical practice recommendations. J Pediatr (Rio J). 2008; 84: 192 - 202. doi: 10.2223/JPED.1773

488. Кузьмина Н.И., Шох Б.П., Никишина И.П. Современный взгляд на системную глюкокортикостероидную терапию при ювенильном ревматоидном артрите//Научно-практическая ревматология. - 2000. - N. 2. - С. 56 - 62.

489. Mouy R. et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases//The Journal of pediatrics. - 1996. - Т. 129. - N. 5. - С. 750 - 754.

490. Georgiadou S, Gatselis NK, Stefos A, et al. Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and infusions. World J Clin Cases. 2019; 7: 3394 - 406. doi: 10.12998/wjcc.v7.i21.3394

491. Sen E. S., Clarke S. L. N., Ramanan A. V. Macrophage activation syndrome//The Indian Journal of Pediatrics. - 2016. - Т. 83. - N. 3. - С. 248 - 253.

492. F. et al. Comparison of baseline laboratory findings of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis and multisystem inflammatory syndrome in children//International Journal of Rheumatic Diseases. - 2021. - Т. 24. - N. 4. - С. 542 - 547.

493. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016; 12: 259 - 68. doi: 10.1038/nrrheum.2015.179

494. Papa R, Natoli V, Caorsi R, et al. Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases. Pediatr Rheumatol. 2020; 18: 56. doi: 10.1186/s12969-020-00450-9

495. Bhat CS, Shetty R, Ramesh D, et al. Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C). Indian Pediatr. 2021; 58: 994 - 6. doi: 10.1007/s13312-021-2340-1

496. Kostik MM, Isupova EA, Belozerov K, et al. Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis. Front Pediatr. 2022; 10: 894846. doi: 10.3389/fped.2022.894846

497. Phadke O, Rouster-Stevens K, Giannopoulos H, et al. Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol. 2021; 19: 98. doi: 10.1186/s12969-021-00585-3

498. Pal P, Bathia J, Giri PP, et al. Macrophage activation syndrome in pediatrics: 10 years data from an Indian center. Int J Rheum Dis. 2020; 23: 1412 - 6. doi: 10.1111/1756-185X.13915

499. Wei A, Ma H, Li Z, et al. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children. Int J Hematol. 2020; 112: 568 - 76. doi: 10.1007/s12185-020-02936-4

500. Kostik MM, Raupov RK, Suspitsin EN, et al. The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience. Front Pediatr. 2022; 10: 820586. doi: 10.3389/fped.2022.820586

501. Conde Santa Yarelis, Mendoza Reynaldo, del Toro Ravelo Laydenis , Chia Proenza Daniel. de de como de la artritis juvenil . Rev Cuba Reumatol [Internet]. 2021 Ago [citado 2022 Ago 02]; 23(2): e209. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962021000200011&lng=es. Epub 01-Ago-2021.

502. Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100: S1 - 276. doi: 10.1016/j.kint.2021.05.021

503. Rao S, Abzug MJ, Carosone-Link P, et al. Intravenous Acyclovir and Renal Dysfunction in Children: A Matched Case Control Study. J Pediatr. 2015; 166: 1462 - 1468.e4. doi: 10.1016/j.jpeds.2015.01.023

504. Kimberlin DW. Acyclovir Dosing in the Neonatal Period and Beyond. J Pediatr Infect Dis Soc. 2013; 2: 179 - 82. doi: 10.1093/jpids/pis138

505. Widasmara D, Firdausiya F. Disseminated Herpes Zoster on a Child with Systemic Lupus Erythematosus and Lupus Nephritis. Infect Drug Resist. 2021; Volume 14: 2777 - 85. doi: 10.2147/IDR.S314220

506. Balfour HH, McMonigal KA, Bean B. Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients. J Antimicrob Chemother. 1983; 12: 169 - 79. doi: 10.1093/jac/12.suppl_B.169

507. Whitley RJ. Herpes simplex virus in children. Curr Treat Options Neurol. 2002; 4: 231 - 7. doi: 10.1007/s11940-002-0040-2

508. Antiviral Drugs in Children and Adolescents. Pediatr Infect Dis. 2020; 1: 123 - 8. doi: 10.5005/jp-journals-10081-1221

509. Adler SP, Marshall B. Cytomegalovirus Infections.; 11.

510. Shim GH. Treatment of congenital cytomegalovirus infection. Clin Exp Pediatr. 2023; 66: 384 - 94. doi: 10.3345/cep.2022.01032

511. Lin X, Wan Y, Liu Y. Efficacy of ganciclovir in the treatment of cytomegalovirus (CMV) infection in infants and its effect on inflammatory reaction and immune function. Am J Transl Res. 2023; 15: 6514 - 23.

512. Zhang S, Zhu Y, Jin Y, et al. Difference between Acyclovir and Ganciclovir in the Treatment of Children with Epstein-Barr Virus-Associated Infectious Mononucleosis. Evid Based Complement Alternat Med. 2021; 2021: 1 - 6. doi: 10.1155/2021/8996934

513. Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013; 162: 376 - 82. doi: 10.1111/bjh.12386

514. Andrews A, Hickling P. Thrombosis associated with antiphospholipid antibody in juvenile chronic arthritis. Lupus. 1997; 6: 556 - 7. doi: 10.1177/096120339700600616

515. Thomas KN, Aggarwal A. Childhood rheumatic diseases: bites not only the joint, but also the heart. Clin Rheumatol. 2023; 42: 2703 - 15. doi: 10.1007/s10067-023-06621-9

516. Carcillo JA, Shakoory B, Castillo L. Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, and Hyperferritinemic Sepsis-Induced Multiple-Organ Dysfunction Syndrome in the Pediatric ICU. In: Mastropietro CW, Valentine KM, eds. Pediatric Critical Care. Cham: Springer International Publishing 2019: 245 - 55.

517. Алексеева Е., Валиева С., Бзарова Т., Семикина Е., Исаева К., Лисицин А., Денисова Р., Чистякова Е., Слепцова Т., Митенко Е. Эффективность и безопасность отечественного рекомбинантного человеческого гранулоцитарного колониестимулирующего фактора при нейтропениях, развивающихся на фоне анти-в клеточной и иммуносупрессивной терапии у больных ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2010; 9(4): 94 - 100.

518. Yilmaz D., Ritchey A.K. Severe neutropenia in children: a single institutional experience//Journal of Pediatric Hematology/Oncology. - 2007. - Т. 29. - N. 8. - С. 513 - 518.

519. Segel, G.B., & Halterman, J.S. (2008). Neutropenia in pediatric practice. Pediatrics in review, 29(1), 12.

520. Jog NR, Young KA, Munroe ME, et al. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Ann Rheum Dis. 2019; 78: 1235 - 41. doi: 10.1136/annrheumdis-2019-215361

521. Demirkol D, Yildizdas D, Bayrakci B, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care. 2012; 16: R52. doi: 10.1186/cc11256

522. El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, et al. Intravenous Polyclonal Immunoglobulin Administration to Sepsis Syndrome Patients: A Prospective Study in a Pediatric Intensive Care Unit. J Trop Pediatr. 2005; 51: 271 - 8. doi: 10.1093/tropej/fmi011

523. Vassilopoulos A, McCormick W, Lakhani A. Update in Hyperferritinemic Syndromes: Recognition and Management - A Scoping Review. J Brown Hosp Med. 2022; 1. doi: 10.56305/001c.37667

524. Henter J-I, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007; 48: 124 - 31. doi: 10.1002/pbc.21039

525. Малахов О.А. и др. Эндопротезирование тазобедренного сустава у подростков, больных ювенильным ревматоидным артритом//Вестник травматологии и ортопедии им. НН Приорова. - 2012. - N. 1. - С. 48 - 52.

526. Sawhney S, Aggarwal A, Springer Malaysia Representative Office. Pediatric Rheumatology A Clinical Viewpoint. 2018.

527. Finch SL, Rosenberg AM, Vatanparast H. Vitamin D and juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2018; 16: 34. doi: 10.1186/s12969-018-0250-0

528. Yamamoto EA, TN. Relationships Between Vitamin D, Gut Microbiome, and Systemic Autoimmunity. Front Immunol. 2020; 10: 3141. doi: 10.3389/fimmu.2019.03141

529. Takken T, Van Brussel M, Engelbert RHH, et al. Exercise therapy in juvenile idiopathic arthritis. Cochrane Database Syst Rev. Published Online First: 23 April 2008. doi: 10.1002/14651858.CD005954.pub2

530. Luttosch F, Baerwald C. Rehabilitation in der Rheumatologie. Internist. 2010; 51: 1239 - 45. doi: 10.1007/s00108-010-2626-1

531. Stucki G, Kroeling P. Physical therapy and rehabilitation in the management of rheumatic disorders. Best Pract Res Clin Rheumatol. 2000; 14: 751 - 71. doi: 10.1053/berh.2000.0111

532. Kuntze G, Nesbitt C, Whittaker JL, et al. Exercise Therapy in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis. Arch Phys Med Rehabil. 2018; 99: 178 - 193.e1. doi: 10.1016/j.apmr.2017.05.030

533. Sarac DC, Bayraktar D, Ozer Kaya D, et al. The effects of inspiratory muscle training on cardiorespiratory functions in juvenile idiopathic arthritis: A randomized controlled trial. Pediatr Pulmonol. 2024; 59: 562 - 73. doi: 10.1002/ppul.26783

534. Elnaggar RK, Mahmoud WS, Abdelbasset WK, et al. Low-energy laser therapy application on knee joints as an auxiliary treatment in patients with polyarticular juvenile idiopathic arthritis: a dual-arm randomized clinical trial. Lasers Med Sci. 2021; 37: 1737 - 46. doi: 10.1007/s10103-021-03427-6

535. Azab AR, Kamel FH, Basha MA, et al. Impact of Clinical Pilates Exercise on Pain, Cardiorespiratory Fitness, Functional Ability, and Quality of Life in Children with Polyarticular Juvenile Idiopathic Arthritis. Int J Environ Res Public Health. 2022; 19: 7793. doi: 10.3390/ijerph19137793

536. Elnaggar RK, Mahmoud WS, Moawd SA, et al. Impact of core stability exercises on bone mineralization and functional capacity in children with polyarticular juvenile idiopathic arthritis: a randomized clinical trial. Clin Rheumatol. 2021; 40: 245 - 53. doi: 10.1007/s10067-020-05219-9

537. Elnaggar RK, Elfakharany MS. Aqua-Plyometric Exercises-Induced Changes in Muscle Strength, Bone Mineral Properties, and Physical Fitness in Patients With Juvenile Idiopathic Arthritis: A 12-Week, Randomized Controlled Trial. Pediatr Exerc Sci. 2023; 35: 198 - 205. doi: 10.1123/pes.2022-0044

538. Tarakci E, Arman N, Tarakci D, et al. Leap Motion Controller-based training for upper extremity rehabilitation in children and adolescents with physical disabilities: A randomized controlled trial. J Hand Ther. 2020; 33: 220 - 228.e1. doi: 10.1016/j.jht.2019.03.012

539. Eid MAM, Aly SM, El-Shamy SM. Effect of Electromyographic Biofeedback Training on Pain, Quadriceps Muscle Strength, and Functional Ability in Juvenile Rheumatoid Arthritis. Am J Phys Med Rehabil. 2016; 95: 921 - 30. doi: 10.1097/PHM.0000000000000524

540. Elnaggar RK, Elshafey MA. Effects of Combined Resistive Underwater Exercises and Interferential Current Therapy in Patients with Juvenile Idiopathic Arthritis: A Randomized Controlled Trial. Am J Phys Med Rehabil. 2016; 95: 96 - 102. doi: 10.1097/PHM.0000000000000347

541. Field T, Hernandez-Reif M, Seligmen S, et al. Juvenile Rheumatoid Arthritis: Benefits from Massage Theraphy. J Pediatr Psychol. 1997; 22: 607 - 17. doi: 10.1093/jpepsy/22.5.607

542. on behalf of PRINTO Egypt, El Miedany Y, El Gaafary M, et al. Shared decision-making aid for juvenile idiopathic arthritis: moving from informative patient education to interactive critical thinking. Clin Rheumatol. 2019; 38: 3217 - 25. doi: 10.1007/s10067-019-04687-y

543. Mulligan K, Hirani SP, Harris S, et al. The Effects of a Web-Based Tool for Parents of Children With Juvenile Idiopathic Arthritis: Randomized Controlled Trial. J Med Internet Res. 2022; 24: e29787. doi: 10.2196/29787

544. N, Nahuelhual Cares P, San P. Efectividad de la terapia Watsu en pacientes con artritis juvenil. Un ensayo controlado paralelo, aleatorio y simple ciego. Rev Chil . 2019; 90: 282. doi: 10.32641/rchped.v90i3.886

545. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011; 63: 465 - 82. doi: 10.1002/acr.20460

546. Houghton K. Physical activity, physical fitness, and exercise therapy in children with juvenile idiopathic arthritis. Phys Sportsmed. 2012; 40: 77 - 82. doi: 10.3810/psm.2012.09.1979

547. Zuk B, Kaczor Z, B, et al. Physiotherapy in pauciarticular juvenile idiopathic arthritis. Case study. Ortop Traumatol Rehabil. 2014; 16: 185 - 95. doi: 10.5604/15093492.1105236

548. Epps H, Ginnelly L, Utley M, et al. Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. Health Technol Assess Winch Engl. 2005; 9: iii - iv, ix - x, 1 - 59. doi: 10.3310/hta9390

549. Chausset A, Pereira B, Echaubard S, et al. Access to paediatric rheumatology care in juvenile idiopathic arthritis: what do we know? A systematic review. Rheumatology. 2020; 59: 3633 - 44. doi: 10.1093/rheumatology/keaa438

550. Scott C, Chan M, Slamang W, et al. Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind. Clin Rheumatol. 2019; 38: 563 - 75. doi: 10.1007/s10067-018-4304-y

551. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79: 39 - 52. doi: 10.1136/annrheumdis-2019-215882

552. Jansen MHA, Rondaan C, Legger GE, et al. EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Ann Rheum Dis. 2023; 82: 35 - 47. doi: 10.1136/annrheumdis-2022-222574

553. Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011; 70: 1704 - 12. doi: 10.1136/ard.2011.150193

554. Кокина М.Ю., Фомина Д.С., Лебедкина М.С., Мутовина З.Ю., Жолобова Е.С., Курбанова С.Х., Наргизян А.К., Фетисова А.Н., Анджель А.Е., Дворяковская Т.М., Шилькрот И.Ю., Алексеева Е.И. Эффективность и безопасность применения двухкомпонентного препарата моноклональных антител к SARS-CoV-2 (тиксагевимаб + цилгавимаб) для доконтактной профилактики новой коронавирусной инфекции у иммунокомпрометированных пациентов детского возраста с ревматическими заболеваниями. Предварительные результаты первого в Российской Федерации проспективного наблюдательного когортного исследования. Вопросы практической педиатрии. 2023; 18(1): 16 - 26

555. Alexeeva EI, Dvoryakovskaya TM, Denisova RV, et al. Immunization With a Pneumococcal Polysaccharide Vaccine in Children With Juvenile Idiopathic Arthritis Without Systemic Manifestations: a Prospective Study. Curr Pediatr. 2017; 16: 493 - 501. doi: 10.15690/vsp.v16i6.1822

556. Lomakina O, Alexeeva E, Dvoryakovskaya T, et al. OP0166 Disease activity in children with juvenile idiopathic arthritis after simultaneous pcv13 and hib vaccination: a cohort study. Ann Rheum Dis. 2021; 80: 100.2 - 100. doi: 10.1136/annrheumdis-2021-eular.3457

557. Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013; 72: 1362 - 6. doi: 10.1136/annrheumdis-2012-202658

558. Alekseeva EI, Van'kova DD, Soloshenko MA, et al. Pneumococcal Vaccine in Patients with Systemic Juvenile Idiopathic Arthritis Receiving Biologic Therapy: International Practice Review. Curr Pediatr. 2019; 18: 101 - 8. doi: 10.15690/vsp.v18i2.2012

559. Alexeeva EI, Soloshenko MA, Dvoryakovskaya TM, et al. Efficacy and Safety of Immunization With Pneumococcal Polysaccharide Vaccine in Children With Juvenile Idiopathic Arthritis: Preliminary Results of a Prospective Open-Label Study. Curr Pediatr. 2017; 16: 142 - 7. doi: 10.15690/vsp.v16i2.1715

560. Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013; 72: 1362 - 6. doi: 10.1136/annrheumdis-2012-202658

561. Garner AJ, Saatchi R, Ward O, et al. Juvenile Idiopathic Arthritis: A Review of Novel Diagnostic and Monitoring Technologies. Healthc Basel Switz. 2021; 9: 1683. doi: 10.3390/healthcare9121683

562. Novelli, V., & Holzel, H. (1999). Safety and tolerability of fluconazole in children. Antimicrobial agents and chemotherapy, 43(8), 1955 - 1960.

563. Тепаев Р.Ф. Синдром диссеминированного внутрисосудистого свертывания у детей. Диагностика и лечение. Педиатрическая Фармакология 2010; 7: 27 - 31.

564. Gurbanov A, E, Botan E, et al. Intravenous Immunoglobulin Use in Pediatric Intensive Care: A Single-Center Experience. 2023.

565. Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis agents). Clin Microbiol Infect. 2018; 24: S10 - 20. doi: 10.1016/j.cmi.2017.12.025

566. Valentine SL, Bembea MM, Muszynski JA, et al. Consensus Recommendations for RBC Transfusion Practice in Critically Ill Children From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2018; 19: 884 - 98. doi: 10.1097/PCC.0000000000001613

567. Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin Replacement Therapy in Children. Immunol Allergy Clin North Am. 2008; 28: 833 - 49. doi: 10.1016/j.iac.2008.07.001

568. Rodriguez MM, Wagner-Weiner L. Intravenous Immunoglobulin in Pediatric Rheumatology: When to Use It and What Is the Evidence. Pediatr Ann. 2017; 46. doi: 10.3928/19382359-20161214-01

569. Scientific Centre of Children's Health, Moscow, Russian Federation, Alexeeva EI, Denisova RV, et al. Intravenous Immunoglobulin in Pediatric Rheumatology Practice. Curr Pediatr Vopr Sovrem Pediatr. 2015; 14: 219 - 23. doi: 10.15690/vsp.v14i2.1290

570. Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology. 2015; 54: 383 - 91. doi: 10.1093/rheumatology/keu429

571. Prasad AN, Chaudhary S. Intravenous immunoglobulin in pediatrics: A review. Med J Armed Forces India. 2014; 70: 277 - 80. doi: 10.1016/j.mjafi.2013.05.011

572. Khojah AM, Miller ML, Klein-Gitelman MS, et al. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases. Pediatr Rheumatol. 2019; 17: 61. doi: 10.1186/s12969-019-0365-y

573. Cuadros E, J, Clemente D, et al. Correction to: Position statement of the Spanish society of pediatric rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: part 1 (screening). Eur J Pediatr. 2022; 181: 2355 - 2355. doi: 10.1007/s00431-022-04448-1

574. Papadopoulou C, Eleftheriou D. How do I ensure safe use of biological agents in children and adolescents with rheumatic diseases? Paediatr Child Health. 2014; 24: 264 - 8. doi: 10.1016/j.paed.2013.10.004

575. Opoka-Winiarska V, Grywalska E, Sobiesiak A, et al. The Impact of Epstein-Barr Virus Infection on Juvenile Idiopathic Arthritis Activity and Patient's Response to Treatment. J Clin Med. 2020; 9: 3453. doi: 10.3390/jcm9113453

576. Consolaro A, Giancane G, Alongi A, et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health. 2019; 3: 255 - 63. doi: 10.1016/S2352-4642(19) 30027-6

577. Xu F, Lee FK, Morrow RA, et al. Seroprevalence of Herpes Simplex Virus Type 1 in Children in the United States. J Pediatr. 2007; 151: 374 - 7. doi: 10.1016/j.jpeds.2007.04.065

578. Aeschlimann FA, Chong S-L, Lyons TW, et al. Risk of Serious Infections Associated with Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analyses. J Pediatr. 2019; 204: 162 - 171.e3. doi: 10.1016/j.jpeds.2018.08.065

579. Santos MJ, H, Conde M, et al. Portuguese recommendations for the use of biological therapies in children and adolescents with juvenile idiopathic arthritis--December 2011 update. Acta Reumatol Port. 2012; 37: 48 - 68.

580. R, HE, M, et al. Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center. Rheumatol Int. 2020; 40: 771 - 6. doi: 10.1007/s00296-019-04498-z

581. Овсянкина Е.С, Губкина М.Ф., Панова Л.В., Юхименко Н.В. Методы скрининга туберкулезной инфекции у детей и их роль в формировании групп риска и диагностике заболевания. Российский педиатрический журнал. 2017; 20 (2): 108 - 115. DOI: http://dx.doi.org/10.18821/1560-9561-2017-20 (2): 108 - 115.

582. Allen V, Longley N. Infections in immunosuppressed travellers with autoimmune inflammatory diseases-a narrative review and advice for clinical practice. Rheumatology. 2021; 60: 3969 - 76. doi: 10.1093/rheumatology/keab445

583. Whyte LA, Al-Araji RA, McLoughlin LM. Guidelines for the management of acute gastroenteritis in children in Europe. Arch Dis Child Educ Pract Ed. 2015; 100: 308 - 12. doi: 10.1136/archdischild-2014-307253

584. J, Roggentin P. Enterale Yersiniosen. Klinische Bedeutung, Epidemiologie, Diagnostik und [Intestinal yersiniosis. Clinical importance, epidemiology, diagnosis, and prevention]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004 Jul; 47(7): 685 - 91

585. Wiger K., E.A., Wathne K.O. Infections in immunosuppressed children//Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin, ny Raekke. - 2005. - Т. 125. - N. 9. - С. 1168 - 1172.

586. Acebo J.J. et al. Infections in Immunosuppressed Pediatric Patients//Pediatric Surgical Oncology. - Cham: Springer International Publishing, 2023. - С. 1 - 34.

587. Society P.I.D. et al. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV//ClinicalInfo. HIV. gov [Internet]. - US Department of Health and Human Services, 2023.

588. Allen UD. Management of infections in the immunocompromised child: General principles. LymphoSign J. 2016; 3: 87 - 98. doi: 10.14785/lymphosign-2016-0007

589. Patrick C.C. Clinical management of infections in immunocompromised infants and children//(No Title). - 2001.

590. Kwiatkowska B, Filipowicz-Sosnowska A. Reactive arthritis. Pol Arch Intern Med. 2009; 119: 60 - 6. doi: 10.20452/pamw.606

591. Sharma AP, Norozi K, Filler G, et al. Diagnosis of Pediatric Hypertension: European Society of Hypertension-recommended 24-hr vs. 24-hr-day-night Ambulatory Blood Pressure thresholds.; 23.

592. Djawe K, Daly KR, Levin L, et al. Humoral Immune Responses to Pneumocystis jirovecii Antigens in HIV-Infected and Uninfected Young Children with Pneumocystis Pneumonia. PLoS ONE. 2013; 8: e82783. doi: 10.1371/journal.pone.0082783

593. F-M, Trusen A, Weig M. Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur J Pediatr. 2002; 161: 563 - 74. doi: 10.1007/s00431-002-1041-6

594. Douglas AP, Smibert Olivia C, Bajel A, et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern Med J. 2021; 51: 143 - 76. doi: 10.1111/imj.15591

595. Armbrust W, Kamphuis SSM, Wolfs TWF, et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology. 2004; 43: 527 - 9. doi: 10.1093/rheumatology/keh074

596. Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014; CD005590. doi: 10.1002/14651858.CD005590.pub3

597. Pneumonia in Immunocompromised Patients: Overview, Causes of Pneumonia, HIV/AIDS. Published Online First: 23 March 2020.

598. What's New Adult and Adolescent Opportunistic Infection. AIDSinfo. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/392/whats-new (accessed 14 April 2020)

599. Aizawa-Yashiro T, Oki E, Tsuruga K, et al. Intravenous immunoglobulin therapy leading to dramatic improvement in a patient with systemic juvenile idiopathic arthritis and severe pericarditis resistant to steroid pulse therapy. Rheumatol Int. 2012; 32: 1359 - 61. doi: 10.1007/s00296-010-1413-6

600. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep. 2009; 58: 1 - 166.

601. Islam MdA, Khandker SS, Alam SS, et al. Vitamin D status in patients with systemic lupus erythematosus (SLE): A systematic review and meta-analysis. Autoimmun Rev. 2019; 18: 102392. doi: 10.1016/j.autrev.2019.102392

602. Galindo-Zavala R, Bou-Torrent R, B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol. 2020; 18: 20. doi: 10.1186/s12969-020-0411-9

603. Денисова Р., Алексеева Е., Пинелис В., Баканов М., Валиева С., Бзарова Т., Исаева К., Морев С., Кузнецова Г. Эффективность и безопасность ибандроновой кислоты для внутривенного введения при тяжелом системном остеопорозе у больных ювенильным артритом. Вопросы современной педиатрии. 2011; 10(6): 83 - 88.

604. Kutilek S, Plasilova I, Langer J. Ibandronate in the treatment of pediatric osteoporosis. Bone Abstr. Published Online First: 9 June 2015. doi: 10.1530/boneabs.4.P80

605. Bachrach LK, Ward LM. Clinical Review: Bisphosphonate Use in Childhood Osteoporosis. J Clin Endocrinol Metab. 2009; 94: 400 - 9. doi: 10.1210/jc.2008-1531

606. Ansell BM, Chamberlain MA. 11 Children with chronic arthritis: the management of transition to adulthood. Baillieres Clin Rheumatol. 1998; 12: 363 - 74. doi: 10.1016/S0950-3579(98)80023-X

607. Nascimento Leite M, Kamper SJ, O'Connell NE, et al. Physical activity and education about physical activity for chronic musculoskeletal pain in children and adolescents. Cochrane Database Syst Rev. 2023; 2023. doi: 10.1002/14651858.CD013527.pub2

608. Loctin A, Bailly F, Laroche D, et al. Clinical interest of bone marrow aspiration in rheumatology: a practice-based observational study of 257 bone marrow aspirations. Clin Rheumatol. 2013; 32: 115 - 21. doi: 10.1007/s10067-012-2097-y

609. R, HE, M, et al. Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center. Rheumatol Int. Published Online First: 21 December 2019. doi: 10.1007/s00296-019-04498-z

610. Aghdashi MA, Khadir M, Dinparasti-Saleh R. Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept. Curr Rheumatol Rev. 2020; 16: 61 - 6. doi: 10.2174/1573397115666190506152729

611. de Camargo MC, Barros BCA, Fulone I, et al. Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting. Front Pharmacol. 2019; 10: 965. doi: 10.3389/fphar.2019.00965

612. Puxeddu I, Giori L, Rocchi V, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2012; 108: 123 - 4. doi: 10.1016/j.anai.2011.11.004

613. Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol Orlando Fla. 2020; 211: 108322. doi: 10.1016/j.clim.2019.108322

614. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial Ramanan, Athimalaipet VViola, Diego et al. The Lancet, Volume 402, Issue 10401, 555 - 570

615. Decker RL, StevenErnest C II, Radtke DB, et al. A populationpharmacokinetic model using allometric scaling forbaricitinib in patients with juvenile idiopathicarthritis. CPT Pharmacometrics Syst Pharmacol.2024; 13: 970 - 981. doi: 10.1002/psp4.13131

616. Ramanan, A.V., Guly, C., Simonini, G., Keller, S., Sen, P., Holzkaemper, T., & Quartier, P. (2024). OP0101 Effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis associated uveitis or chronic anterior antinuclear antibody positive uveitis in children.

617. Thomas J, Kuthyar S, Shantha JG, Angeles-Han ST, Yeh S. Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis. Ann Eye Sci. 2021 Jun; 6: 19. doi: 10.21037/aes-2019-dmu-10. Epub 2021 Jun 15. PMID: 34131629; PMCID: PMC8202723.

618. Алексеева, Е.И., and Т.М. Бзарова. "Ювенильный артрит: возможности медикаментозного и немедикаментозного лечения на современном этапе." Лечащий врач 9 (2011): 60 - 60.